NIH_SPENDING_CATS: Cancer;Immunotherapy;Stem Cell Research;Stem Cell Research - Nonembryonic - Human

PI_NAMEs: SHEN, MICHAEL M. (contact)

PROJECT_TERMS: 3-Dimensional;Address;Advocacy;African American;anti-cancer research;Applications Grants;Area;Back;Biology;Biomedical Engineering;Cancer Biology;cancer cell;Cancer Center Support Grant;cancer immunotherapy;cancer stem cell;career;Catchment Area;Cell Communication;Cell Lineage;Cell Physiology;cell type;Cells;Cellular Structures;cellular targeting;Clinic;Clinical;Clinical Data;Clinical Research;Clinical Trials;Collaborations;Development;Digestive System Disorders;Doctor of Philosophy;Elements;Epithelial Cells;Epithelium;Faculty;Faculty Recruitment;Fellowship;Fostering;Funding;Future;Genetic;Genitourinary system;Goals;Grant;Growth;Human;Immune;immune checkpoint;immunoregulation;Immunotherapeutic agent;Immunotherapy;improved;Inflammation;Infrastructure;innovation;insight;Interdisciplinary Study;International;Investigation;Journals;K-Series Research Career Programs;Laboratories;Laboratory Finding;Lead;Leadership;Liver diseases;Malignant neoplasm of pancreas;Malignant neoplasm of prostate;Malignant Neoplasms;Medicine;meetings;member;men;Mentors;Mentorship;minority patient;Modeling;Molecular;Names;neoplasm immunotherapy;neoplastic cell;nerve supply;Neurons;novel;novel therapeutics;Oncology;Organoids;Pathway interactions;Peer Review;Phase I Clinical Trials;Population;pre-clinical;precision oncology;preclinical study;Process;professor;programs;Publications;Qualifying;recruit;Regulatory T-Lymphocyte;Research;Research Personnel;Resistance;Resource Sharing;Scientist;self-renewal;Signal Pathway;Specific qualifier value;stem;stem cell fate specification;stem cell niche;stem cells;stemness;Strategic Planning;Stromal Cells;Suppressor-Effector T-Lymphocytes;Systems Biology;targeted treatment;Therapeutic Intervention;Time;tissue stem cells;Training;transdifferentiation;Translating;translational scientist;translational study;Translations;triple-negative invasive breast carcinoma;tumor;Tumor Biology;tumor growth;tumor immunology;tumor initiation;tumor microenvironment;Underrepresented Minority;Urology;Vision

PROJECT_TITLE: Tumor Biology and Microenvironment Program


ADMINISTERING_IC: CA

ARRA_FUNDED: N

FUNDING_MECHANISM: RESEARCH CENTERS

IC_NAME: NATIONAL CANCER INSTITUTE

NIH_SPENDING_CATS: Cancer;Cancer Genomics;Genetics;Human Genome;Precision Medicine

ORG_CITY: NEW YORK

ORG_COUNTRY: UNITED STATES

ORG_FIPS: US

ORG_NAME: COLUMBIA UNIVERSITY HEALTH SCIENCES

ORG_STATE: NY

PI_NAMEs: CALIFANO, ANDREA  (contact)

PROJECT_TERMS: Address;Adoption;anti-cancer research;Award;Basic Science;Biology;Biomedical Engineering;Biomedical Research;Cancer Center Support Grant;cancer clinical trial;cancer genomics;career;Catchment Area;Cells;Cellular biology;CLIA certified;Clinic;Clinical;Clinical Research;clinical translation;Clinical Trials;Collaborations;Complement;Complex;Dependence;Direct Costs;Disease;Disparity;drug sensitivity;Elements;Enrollment;Ensure;epigenomics;Evolution;Funding;gene product;Genes;Genomics;Goals;Heterogeneity;Home;imaging biomarker;Immune;Immunooncology;Immunotherapy;improved;Individual;individualized medicine;innovation;Institution;interest;Intervention;Intervention Trial;Investigational Therapies;investigator-initiated trial;Journals;Leadership;Mainstreaming;Malignant Neoplasms;meetings;Melanoma;member;Methodology;Modeling;Modification;Molecular;multidisciplinary;multiple omics;Mutation;novel;oncogene addiction;Oncogenes;Organoids;patient derived xenograft model;Patients;Peer Review;Pharmaceutical Preparations;Pharmacotherapy;Phase;Phenotype;pre-clinical;Pre-Clinical Model;precision oncology;programs;Proteins;Publications;Recruitment Activity;Research;Research Personnel;resilience;Resource Sharing;response;RNA;Role;Schools;Services;Signal Transduction;Source;Structure;System;Systems Biology;targeted treatment;Technology;Testing;Therapeutic;Tissues;tool;Training Activity;Translating;translational pipeline;Translations;tumor;Tumor Biology;tumor heterogeneity;tumor initiation;tumor microenvironment;Underrepresented Minority;United States National Institutes of Health;Universities

PROJECT_TITLE: Precision Oncology and Systems Biology Program

STUDY_SECTION: NCI

STUDY_SECTION_NAME: Cancer Centers Study Section (A)[NCI-A]


ADMINISTERING_IC: HL

ED_INST_TYPE: SCHOOLS OF MEDICINE

FUNDING_MECHANISM: NON-SBIR/STTR RPGS

IC_NAME: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

NIH_SPENDING_CATS: Cancer;Cardiovascular;Clinical Research;Heart Disease;Lung;Lung Cancer;Prevention;Radiation Oncology

ORG_CITY: PHILADELPHIA

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_NAME: UNIVERSITY OF PENNSYLVANIA

ORG_STATE: PA

PHR: Project Narrative Radiation therapy (RT) is a highly effective treatment for lung cancer but carries a risk of cardiotoxicity that limits gains in cancer control and survival. Our multidisciplinary biomarker and imaging study is the critical first step to improve cardiovascular risk stratification and the personalized delivery of RT.

PI_NAMEs: KY, BONNIE  (contact)

PROGRAM_OFFICER_NAME: DESVIGNE-NICKENS, PATRICE

PROJECT_TERMS: Address;Affect;Biological;Biological Markers;Blood Vessels;Cancer Control;Cancer Etiology;Cancer Patient;cancer survival;Cardiac;Cardiomyopathies;cardioprotection;Cardiotoxicity;Cardiovascular Physiology;cardiovascular risk factor;Cardiovascular system;Cessation of life;chemoradiation;Chest;circulating biomarkers;Clinical;Cohort Studies;Collaborations;Coronary heart disease;Data;Disease;Dose;effective therapy;experience;Functional disorder;Heart;Heart failure;High Prevalence;high risk population;Hospitals;Image;imaging biomarker;imaging study;improved;In Vitro;in vivo;Inflammation;innovation;Institution;Intervention;Longitudinal cohort;Malignant neoplasm of lung;Malignant Neoplasms;Measures;Methods;Microvascular Dysfunction;Morbidity - disease rate;mortality;Multicenter Studies;multidisciplinary;Non-Small-Cell Lung Carcinoma;Oncology;Outcome;Oxidative Stress;Pathway interactions;patient subsets;Patient-Focused Outcomes;Patients;Pennsylvania;Perfusion;Phenotype;prognostic value;Prospective cohort;radiation delivery;Radiation Dose Unit;Radiation Oncology;Radiation therapy;Radiation Therapy Oncology Group;Radiology Specialty;randomized, clinical trials;Research Priority;response;Risk;risk prediction;risk stratification;Role;Solid Neoplasm;Stress;Toxic effect;United States National Institutes of Health;Universities;Vascular Diseases;Washington;Woman;Work

PROJECT_TITLE: Mechanistic Risk Prediction of Radiation Therapy Cardiotoxicity

STUDY_SECTION: CHSA

STUDY_SECTION_NAME: Cancer, Heart, and Sleep Epidemiology A Study Section[CHSA]


NIH_SPENDING_CATS: Behavioral and Social Science;Cancer;Clinical Research;Dissemination and Implementation Research;Health Services;Palliative Care;Prevention

PI_NAMEs: HERSHMAN, DAWN  (contact)

PROJECT_TERMS: Address;Adherence;Advocate;Affect;Agreement;anti-cancer research;Area;Biological Markers;Cancer Burden;cancer care;Cancer Center;Cancer Center Support Grant;Cancer Control;cancer diagnosis;cancer epidemiology;Cancer Etiology;cancer prevention;cancer risk;Cancer Survivorship;cancer therapy;care delivery;Catchment Area;chemical carcinogenesis;Chemoprevention;clinical risk;Clinical Trials;Cohort Studies;Collaborations;collaborative environment;Communities;Community Health Education;Continuity of Patient Care;cost effective;cost effective treatment;Creativeness;Data;Decision Aid;density;Development;Direct Costs;Discipline;Disparity;dissemination research;Doctor of Philosophy;Early Diagnosis;Educational Activities;energy balance;Enrollment;Epidemiologist;epidemiology study;Etiology;experience;Faculty;Fostering;Funding;Future;Genetic;global health;Goals;Growth and Development function;Health;Health system;imaging biomarker;implementation research;implementation strategy;improved;Institution;Intervention;intervention delivery;Intervention Studies;Intervention Trial;investigator-initiated trial;Journals;Laboratories;Lead;Leadership;Life Cycle Stages;life span;Life Style;Malignant Breast Neoplasm;Malignant Neoplasms;Medical Oncologist;member;mentoring community;Mentorship;minority patient;Modeling;Molecular;Molecular Epidemiology;Molecular Genetics;Multicenter Trials;Newly Diagnosed;Observational Study;organizational structure;Outcome;outreach;Palliative Care;Pathway interactions;Patients;Pattern;Peer Review;Pilot Projects;Policies;Population;Population Sciences;Prevention;Primary Prevention;programs;Provider;Publications;recruit;Research;Research Personnel;Research Priority;Resource Sharing;Resources;Risk;Risk Assessment;Schools;screening;Secondary Prevention;Site;Source;Supportive care;survivorship;symptom management;Time;Translating;Underrepresented Minority;United States National Institutes of Health;Woman

PROJECT_TITLE: Cancer Population Science Program


NIH_SPENDING_CATS: Cancer

PI_NAMEs: RUSTGI, ANIL K (contact)

PROJECT_TERMS: Accountability;Active Listening;anti-cancer research;Calibration;Cancer Center;Cancer Center Support Grant;career;Caring;Charge;Clinic;Clinical;clinical care;Clinical Trials;Collaborations;Communities;community advisory board;community engagement;Community Outreach;Comprehensive Cancer Center;Decision Making;Education;Evaluation;expectation;experience;Feedback;Fostering;Future;Goals;Growth;Herbert Irving Comprehensive Cancer Center;implementation strategy;innovation;Institution;Leadership;Malignant Neoplasms;meetings;Mission;Pennsylvania;Process;Productivity;programs;Recommendation;recruit;Research;Resource Allocation;Resource Sharing;Science;Shapes;Strategic Planning;Structure;success;Time;Translating;translational scientist;Translations;Universities;Vision

PROJECT_TITLE: Leadership, Planning, and Evaluation


NIH_SPENDING_CATS: Cancer;Clinical Research

PROJECT_TERMS: Acceleration;Address;anti-cancer research;Area;Award;base;Budgets;Cancer Center Support Grant;career;Catchment Area;Categories;Clinical;Clinical Research;Clinical Sciences;Data;Development;Direct Costs;Effectiveness;Event;Fostering;Funding;Funding Agency;Funding Mechanisms;Grant;Growth;Herbert Irving Comprehensive Cancer Center;high reward;high risk;hospital utilization;Industry;innovation;Institution;inter-institutional;interdisciplinary collaboration;Investments;Malignant Neoplasms;multidisciplinary;New York;novel;Peer Review;Pilot Projects;Play;Population;Population Research;Population Sciences;pre-clinical;Presbyterian Church;Probability;Process;programs;Research;Research Personnel;Research Priority;Resource Sharing;Role;Science;Source;Strategic Planning;Technology;Therapeutic;Translational Research;Universities;Vision

PROJECT_TITLE: Developmental Funds


NIH_SPENDING_CATS: Aging;Breast Cancer;Burden of Illness;Cancer;Cardiovascular;Clinical Research;Comparative Effectiveness Research;Cost Effectiveness Research;Disability Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Precision Medicine;Prevention;Women's Health Research

ORG_CITY: Oakland

ORG_NAME: KAISER FOUNDATION RESEARCH INSTITUTE

ORG_STATE: CA

PHR: Project Narrative Advances in early detection and treatment of cancer has improved 5-year survival, however cardiotoxicity of lifesaving cancer treatment can interfere with it’s planned completion and lead to sub-optimal cancer outcomes and increased downstream morbidity, cost and mortality. We propose to evaluate comparative effectiveness of primary prevention on short-term and long-term cardiovascular, and cancer outcomes, medical expenditures, financial toxicity, and disability in adults with breast cancer. Completion of the aims will guide healthcare policy on primary prevention, improve patient outcomes and identify subgroups of who may benefit the most.

PI_NAMEs: KAWATKAR, ANIKET A (contact)

PROJECT_TERMS: Address;Adult;American;American Heart Association;American Society of Clinical Oncology;Anthracycline;Anti-Hypertensive Agents;Atherosclerosis;Biochemistry;Breast Cancer Patient;Cancer Patient;cancer recurrence;Cancer Survivor;cancer therapy;Cardiology;Cardiotoxicity;Cardiovascular Diseases;cardiovascular disorder risk;Cardiovascular system;Categories;chemotherapy;Chemotherapy-Oncologic Procedure;clinical practice;cohort;college;comparative effectiveness;compare effectiveness;Computerized Medical Record;cost;cost effective;cost effectiveness;Data;Data Set;Decision Making;disability;Disease;Disease Outcome;Dose;Early Diagnosis;Early treatment;Economic Burden;economic outcome;electronic medical record system;Event;evidence base;experience;Financial Support;financial toxicity;Functional disorder;Future;Goals;Guidelines;Health;health care service organization;Health Expenditures;Health Policy;Healthcare;healthy lifestyle;Heterogeneity;high risk population;Histopathology;improved;Incidence;Income;Informatics;Infrastructure;innovation;Interdisciplinary Study;Investments;Lead;Life;Long-Term Effects;Longterm Follow-up;Malignant Breast Neoplasm;Malignant Neoplasms;Medical;Medical Care Costs;Medical Oncologist;Methods;Modeling;Monitor;Morbidity - disease rate;Morphology;mortality;multimodality;Myocardial dysfunction;neoplasm registry;Observational Study;Oncologist;Oncology;Outcome;Outcome Study;patient subsets;Patient-Focused Outcomes;Patients;Pharmaceutical Preparations;pharmacologic;Policies;Policy Analysis;Policy Making;prevent;Prevention;Prevention Guidelines;Prevention therapy;Primary Prevention;programs;Progression-Free Survivals;Radiation Oncologist;Recommendation;Recurrence;Regimen;relative effectiveness;Research;Resources;Retrospective cohort;Risk;risk stratification;Security;Societies;Subgroup;targeted treatment;Techniques;treatment and outcome;treatment choice;treatment effect;treatment response;Treatment-Related Cancer;tumor;United States Social Security Administration

PROJECT_TITLE: Primary Prevention to Reduce Cardiovascular Morbidity and Optimize Cancer Outcomes

STUDY_SECTION: HSQE

STUDY_SECTION_NAME: Health Services: Quality and Effectiveness Study Section[HSQE]


NIH_SPENDING_CATS: Behavioral and Social Science;Breast Cancer;Cancer;Clinical Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Prevention;Primary Health Care;Social Determinants of Health;Women's Health Research

PI_NAMEs: TERRY, MARY BETH  (contact)

PROJECT_TERMS: Acceleration;Address;anti-cancer research;Area;Breast Cancer Detection;Cancer Burden;cancer care;Cancer Center Support Grant;cancer clinical trial;Cancer Control;cancer health disparity;Cancer Hospital;cancer prevention;cancer risk;Caregivers;Catchment Area;Cervical;Clinical Treatment;Clinical Trials;Colon;Colorectal Cancer;Communities;community advisory board;community based participatory research;community burden;community engaged research;community engagement;Community Health;Community Health Education;Community Outreach;community partners;Continuity of Patient Care;County;Diagnosis;Doctor of Philosophy;Early Diagnosis;Education;Educational workshop;Enrollment;Ensure;Environmental Carcinogens;ethnic diversity;Ethnic Origin;evidence base;Evidence based practice;experience;Faculty;Family;Funding;Health;Health Educators;health literacy;Health Services Accessibility;Height;Herbert Irving Comprehensive Cancer Center;Hispanic;Household;Human Papilloma Virus Vaccination;improved;Incidence;Individual;Institution;Intervention;Malignant Breast Neoplasm;Malignant neoplasm of cervix uteri;Malignant neoplasm of liver;Malignant neoplasm of prostate;Malignant Neoplasms;Mammography;Methods;Minority Enrollment;Minority Participation;Mission;Monitor;mortality;Multilingualism;Neighborhoods;New Jersey;New York;New York City;operation;Outcome;outreach;patient oriented;Patients;Persons;Physical activity;Policies;Population;Population Heterogeneity;Population Sciences;Poverty;Presbyterian Church;Prevention;prevention service;Preventive service;Primary Cancer Prevention;Primary Prevention;Program Development;programs;Race;Research;Resources;Risk Factors;screening;Screening for cancer;screening services;Smoking;Socioeconomic Status;survivorship;synergism;treatment services;Uninsured;Vaccination;vaccine acceptance;Washington

PROJECT_TITLE: Community Outreach and Engagement


NIH_SPENDING_CATS: Aging;Cancer;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Patient Safety;Pediatric;Pediatric Cancer;Rare Diseases

PI_NAMEs: LASSMAN, ANDREW B (contact)

PROJECT_TERMS: Adolescent and Young Adult;Age;Age disparity;age group;anti-cancer research;Cancer Center Support Grant;cancer clinical trial;career;Catchment Area;Child;Childhood;Clinical Data;Clinical Nursing Research;Clinical Protocols;Clinical Research;Clinical Trials;Clinical Trials Network;Collaborations;Communication;Data;data integrity;data management;data repository;Diagnosis;early onset;Eligibility Determination;Enrollment;Ensure;Ethnic Origin;Fostering;Gender;Good Clinical Practice;Herbert Irving Comprehensive Cancer Center;Hospitals;human old age (65+);Individual;Infrastructure;Institution;Intervention;Intervention Studies;Intervention Trial;Leadership;Learning;life span;Malignant Neoplasms;Medical center;member;Minority;Minority Health Research;Monitor;New York;Office Management;older adult;Oncology;Participant;patient population;patient safety;Patients;Pediatric Oncology Group;Performance;Policies;Presbyterian Church;Procedures;process improvement;programs;Progress Reports;Protocol Compliance;protocol development;Protocols documentation;quality assurance;Quality Control;Race;real time monitoring;recruit;Reporting;repository;Research;Research Personnel;research study;Research Support;Resources;Risk;Safety;Serious Adverse Event;Services;sex;Socioeconomic Status;Strategic Planning;Training;Training and Education;Underrepresented Minority;United States National Institutes of Health;Universities;Woman

PROJECT_TITLE: Clinical Protocol and Data Management


PI_NAMEs: FOJO, ANTONIO TITO (contact)

PROJECT_TERMS: Address;Affect;Age disparity;age group;Amendment;Cancer Center Support Grant;Cancer Intervention;Catchment Area;Clinical Research;Clinical Research Protocols;Collaborations;Data;Disease;Ensure;expedited review;Goals;Herbert Irving Comprehensive Cancer Center;innovation;Institutional Review Boards;Intervention;Intervention Studies;Intervention Trial;Malignant Neoplasms;Medical center;Monitor;Process;programs;Protocols documentation;Recommendation;Research;Research Priority;research study;Resources;Review Committee;Safety;Scientific Evaluation;sound;System;Time;underserved minority;Universities;Vision;Woman

PROJECT_TITLE: Protocol Review and Monitoring System


FUNDING_MECHANISM: OTHER RESEARCH-RELATED

NIH_SPENDING_CATS: Cancer;Clinical Research;Clinical Trials and Supportive Activities

ORG_CITY: NASHVILLE

ORG_NAME: VANDERBILT UNIVERSITY MEDICAL CENTER

ORG_STATE: TN

PHR: PROJECT NARRATIVE The Vanderbilt Clinical Oncology Research Career Development Program (VCORCDP) is designed to train physician scientists and clinical investigators to perform highly impactful clinical, population-based, and translational studies in oncology. The research includes direct patient assessment, measurements on patient- derived samples, and/or the use of investigational therapeutic or diagnostic techniques. The career development program is composed of this mentored research as well as scholarly activity that provides training in areas such as study design, ethical and scientific responsibilities and rigor and reproducibility required of an investigator.

PI_NAMEs: FRIEDMAN, DEBRA L. (contact);HURLEY, PAULA JILL

PROGRAM_OFFICER_NAME: DAMICO, MARK W

PROJECT_TERMS: Acceleration;Address;Advanced Malignant Neoplasm;Advisory Committees;anti-cancer research;Cancer Biology;cancer care;Cancer Center;Cancer Research Project;career;career development;clinical investigation;Clinical Oncology;Clinical Oncology Supplement (K12);Clinical Research;Clinical Trials;Communities;Continuity of Patient Care;Coupled;design;Development Plans;drug development;education pathway;Ensure;Epidemiologist;Epidemiology;experience;Exposure to;Faculty;Female;Funding;Health;Individual;K-Series Research Career Programs;Lead;Learning;male;Malignant Neoplasms;Manuscripts;Master of Science;Medical Oncologist;medical specialties;meetings;Mentors;Mentorship;Monitor;multidisciplinary;Oncology;Outcome;Participant;patient oriented;patient oriented research;Pediatric Oncologist;peer;Peer Review Grants;Physicians;Population Sciences;Preparation;programs;Progress Reports;Publications;Publishing;Research;Research Personnel;Scholars Program;Scientist;skill acquisition;skills;Structure;success;tool;Training;Translational Research;workforce needs

PROJECT_TITLE: Vanderbilt Clinical Oncology Research Career Development Award

STUDY_SECTION_NAME: Institutional Training and Education Study Section (F)[NCI-F]


NIH_SPENDING_CATS: Breast Cancer;Cancer;Hematology;Women's Health Research

ORG_CITY: SAINT LOUIS

ORG_DEPT: ORTHOPEDICS

ORG_NAME: WASHINGTON UNIVERSITY

ORG_STATE: MO

PHR: Program Director/Principal Investigator (Last, First, Middle): Faccio, Roberta, PhD Narrative  The proposed studies will identify the primary tumor-bone relationship and mechanisms involved in creating an immune suppressive environment via production of Dkk1. OMB No. 0925-0001/0002 (Rev. 03/16 Approved Through 10/31/2018) Page 1 Continuation Format Page

PI_NAMEs: FACCIO, ROBERTA  (contact)

PROGRAM_OFFICER_NAME: WOODHOUSE, ELIZABETH

PROJECT_TERMS: 4T1;Affect;antitumor effect;beta catenin;Biological Assay;bone;Bone Development;Bone Marrow;Bone neoplasms;Bone Resorption;Bone Tissue;Breast Cancer Cell;Breast Cancer Model;Breast Cancer Patient;Breast Carcinoma;Cancer Patient;Cell Differentiation process;cell killing;Cell Proliferation;Cells;Clinical;Cluster Analysis;Communication;cytokine;Data;Development;Disseminated Malignant Neoplasm;Distal;Doctor of Philosophy;Environment;Fibroblasts;Future;Goals;Granulocyte-Macrophage Colony-Stimulating Factor;Growth;Hematopoiesis;Hematopoietic;Homeostasis;Immune;Immunologic Surveillance;immunoregulation;Immunosuppression;In Vitro;in vivo;Inflammatory;inhibitor;Interleukin-6;Lead;Lewis Lung Carcinoma;Macrophage Colony-Stimulating Factor;Malignant Breast Neoplasm;Malignant Neoplasms;Mammary Neoplasms;Melanoma;Mesenchymal;Mouse Mammary Tumor Virus;mouse model;Mus;Myelogenous;Myeloid Cells;Myeloid-derived suppressor cells;Natural Killer Cells;Neoplasm Metastasis;neoplastic cell;Newly Diagnosed;Organ;orthotopic breast cancer;Osteoblasts;Osteocytes;Osteogenesis;overexpression;Play;polyoma middle tumor antigen;Population;primary bone cancer;Primary Neoplasm;Principal Investigator;Production;Prognosis;programs;Proteins;Publishing;Regulation;Reporting;Role;single-cell RNA sequencing;Site;Source;Spleen;Suppressor-Effector T-Lymphocytes;T-Cell Activation;T-Cell Proliferation;T-Lymphocyte;Tissue Microarray;TNFSF11 gene;tumor;tumor growth;tumor progression;Tumor stage;WNT Signaling Pathway;Work

PROJECT_TITLE: Role of Bone in Primary and Metastatic Cancer

STUDY_SECTION: TME

STUDY_SECTION_NAME: Tumor Microenvironment Study Section[TME]


ADMINISTERING_IC: AR

IC_NAME: NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

NIH_SPENDING_CATS: Clinical Research;Microbiome

ORG_CITY: LOS ANGELES

ORG_NAME: UNIVERSITY OF CALIFORNIA LOS ANGELES

PHR: RELEVANCE TO PUBLIC HEALTH Acne, the most common human skin disease, is associated with C. acnes, affects over 50 million people in the U.S., and has a significant psychological impact on patients affecting their self-esteem. This study will provide greater fundamental insights into mechanisms of how T helper cells primed by healthy skin commensals serve as a line of defense against breaching pathogens in acne. The discovery of C. acnes ligands will lead to the development of novel therapeutic approaches dysbiosis. for controlling acne and other human skin diseases caused by

PI_NAMEs: AGAK, GEORGE W (contact)

PROGRAM_OFFICER_NAME: UNDALE, ANITA H

PROJECT_TERMS: Acne;Acne Vulgaris;Affect;Affinity;anti-microbial peptide;Antigen-Presenting Cells;antimicrobial;Bacteria;Binding;Biological;Biopsy;Carbohydrates;Cell Differentiation process;cell type;Cells;Chromatin;Chronic;clinical investigation;Clone Cells;Complex;Coupled;Cutaneous;Data;Defense Mechanisms;Dendritic Cells;design;Development;disability;Disease;DNA;dysbiosis;Education;Equilibrium;experimental study;Exposure to;extracellular;Future;Gene Expression Profile;Genes;genetic element;genetic signature;Goals;Helper-Inducer T-Lymphocyte;Histone H2B;Histones;Homeostasis;Host Defense;Human;IL17 gene;Image;Immune;Immune response;Immune system;Immunologic Techniques;improved;Inflammasome;Inflammation;Inflammatory;Inflammatory Response;innovation;insight;Interferons;Interleukin-10;Journals;keratinocyte;Lesion;Ligands;lipidomics;Lipoproteins;Mass Spectrum Analysis;Mediating;Medical Care Costs;Metagenomics;Methodology;microbial;microbiome;microbiome sequencing;Modeling;Molecular;monocyte;neutrophil;Nonlytic;novel;novel strategies;novel therapeutic intervention;Nucleotides;pathogen;pathogenic bacteria;Pathway interactions;Patients;Persons;Play;potential biomarker;Probiotics;Proteomics;Psychological Impact;Psychological Stress;Public Health;receptor;Research;Resolution;response;Role;Scanning Electron Microscopy;self esteem;Signal Transduction;single-cell RNA sequencing;Skin;skin biopsy;skin disorder;skin lesion;skin microbiome;Specificity;Staphylococcus aureus;Stimulus;T-Lymphocyte;targeted treatment;Testing;therapeutic target;TLR1 gene;TLR2 gene;TLR6 gene;transcriptomics;whole genome

PROJECT_TITLE: Th17 extracellular trap-mediated antimicrobial host defense in acne vulgaris

STUDY_SECTION: ACTS

STUDY_SECTION_NAME: Arthritis, Connective Tissue and Skin Study Section[ACTS]


ORG_CITY: BOSTON

ORG_NAME: DANA-FARBER CANCER INST

ORG_STATE: MA

PHR: Project Narrative Our overarching goal is to identify the molecular mechanisms underlying the observation that human cancers select for particular combinations of mutations in oncogenes and tumor suppressor genes. In this study, we will use genetically engineered primary organoid cultures and mouse models to determine (1) if/how KRAS alleles differ in their abilities to promote colorectal cancer (CRC) progression and to affect the response to standard- of-care and experimental targeted therapies, (2) whether KRAS exhibits allele-specific genetic interactions with other genes mutated in CRC, and (3) whether epithelial cells expressing mutant K-Ras restructure the immune component of the tumor microenvironment to expose therapeutic vulnerabilities. These studies will be critical for understanding the complex and clinically important relationships between oncogene genetics, environmental inputs, and therapeutic responses.

PI_NAMEs: HAIGIS, KEVIN  (contact)

PROGRAM_OFFICER_NAME: WATSON, JOANNA M

PROJECT_TERMS: Address;Affect;Agonist;Alleles;American;Behavior;Biochemical;Bioinformatics;Biological;Biology;cancer genome;cancer initiation;Cancer Patient;cancer therapy;cancer type;Cell Physiology;Cells;checkpoint therapy;Clinical;Clinical Data;Clinical Trials;Code;Codon Nucleotides;Colorectal Cancer;colorectal cancer progression;colorectal cancer treatment;Complex;conventional therapy;Data;Data Set;Disease;drug sensitivity;effective therapy;Engineering;epidemiologic data;Epidemiology;epidemiology study;Epithelial Cells;Exhibits;Exposure to;FDA approved;Fluorouracil;Frequencies;Genes;Genetic;Genetic Engineering;Genetic Screening;Genetically Engineered Mouse;genotyped patients;Goals;Grant;Growth;Human;Immune;immune function;immunomodulatory therapies;Immunotherapy;inhibitor;K-ras mouse model;Knowledge;KRAS2 gene;Large-Scale Sequencing;Malignant Neoplasms;MCC gene;Medical;Medical Oncology;Missense Mutation;Molecular;mouse model;Mus;mutant;Mutate;Mutation;novel therapeutic intervention;novel therapeutics;Oncogenes;Oncogenic;Oncoproteins;Organoids;Outcome;Pathway interactions;Patients;Physicians;Population;precision medicine;Primary Neoplasm;Property;Proteomics;ras Proteins;Receptor Signaling;Resistance;response;Shapes;Signal Pathway;Signal Transduction;Source;standard of care;System;targeted treatment;Therapeutic;Toll-like receptors;treatment response;tumor;tumor growth;tumor microenvironment;tumor progression;Tumor Suppressor Genes;tumorigenesis;United States;Validation;Work

PROJECT_TITLE: Mouse models of Kras-mutant colorectal cancer

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-OTC-N(55)R]


ADMINISTERING_IC: DE

ED_INST_TYPE: SCHOOLS OF DENTISTRY/ORAL HYGN

IC_NAME: NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH

NIH_SPENDING_CATS: Bioengineering;Biotechnology;Dental, Oral, and Craniofacial Disease;Networking and Information Technology R&D (NITRD);Precision Medicine;Regenerative Medicine

ORG_DEPT: DENTISTRY

PHR: Project Narrative In the United States, 30% of adults have oral disease associated tooth loss with this number expected to grow  further over the next two decades. One reason for the poor oral health in the United States is the severe shortage  of dental scientists, that are trained to translate basic science findings and technological advances to dental  clinical practice. In this proposal, we are providing biomedical engineering research training to dentists and  dental students, fostering a new generation of dental scientists who will lead the design and clinical translation  of innovative dental treatments and prevention strategies, and ultimately advancing oral health care and practice.

PI_NAMEs: WADHWA, SUNIL  (contact)

PROGRAM_OFFICER_NAME: MCGUIRL, MICHELE

PROJECT_TERMS: Adult;Area;Big Data;Biocompatible Materials;bioimaging;Biomechanics;Biomedical Engineering;cellular engineering;Clinical;college;Computerized Medical Record;Country;craniofacial;deep learning;Degree program;Dental;Dental General Practice;Dental Instruments;Dental Research;Dental Schools;Dentistry;Dentists;Detection;Diagnostic;digital;Doctor of Philosophy;Education;engineered stem cells;Engineering;Ensure;Faculty;frontier;Funding;Generations;Goals;Grant;Health Occupations;Health Sciences;Image;Investments;Location;Medicine;Modeling;Mouth Diseases;multidisciplinary;next generation;Oral health;patient health information;Patients;personalized medicine;Positioning Attribute;Postdoctoral Fellow;pre-doctoral;Precision therapeutics;Productivity;Program Sustainability;programs;Provider;Puerto Rico;Regenerative engineering;Research;Research Personnel;Research Training;Schools;Science;Scientist;synthetic biology;Time;Tissue Engineering;Training;Training Programs;Underrepresented Populations;Universities

PROJECT_TITLE: Dental-Biomedical Engineering Scholars Training (D-Best) Program


ADMINISTERING_IC: GM

IC_NAME: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

ORG_CITY: LA JOLLA

ORG_DEPT: SURGERY

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN DIEGO

PHR: Narrative: Sepsis is a highly lethal disorder due to uncontrolled infection and multiple organ dysfunction. It is the major cause of death in most intensive care units in the United States. This program seeks to identify novel immune therapies that will reduce the risk of organ failure and improve the ability of patients to respond to and eliminate invading microorganisms.

PI_NAMEs: JUNGER, WOLFGANG G (contact)

PROGRAM_OFFICER_NAME: ZHAO, XIAOLI

PROJECT_TERMS: autocrine;Bacterial Infections;Biological Response Modifiers;Cause of Death;Cell Physiology;Cells;Circulation;Coenzyme A;Coenzymes;Consumption;Critical Care;Defect;Disease;effective therapy;Feedback;fighting;Functional disorder;Goals;Health;Homeostasis;Host Defense;Immune;immune function;Immune System Diseases;immunoregulation;Immunosuppression;Immunotherapy;Impairment;improved;improved outcome;Infection;Inflammation;innovation;Intensive Care Units;Intercept;Intervention;Invaded;Knowledge;Laboratories;Metabolic;Metabolism;microorganism;Mitochondria;mitochondrial dysfunction;mitochondrial metabolism;Molecular;Morbidity - disease rate;mortality;Multiple Organ Failure;neutrophil;novel;Nucleotides;Organ;Organ failure;Outcome;pathogen;Patients;Persons;pharmacologic;prevent;Process;programs;Purinoceptor;Research;response;Risk Reduction;Sepsis;septic patients;Signal Pathway;Signal Transduction;Sirtuins;synergism;T-Lymphocyte;therapeutic target;Time;trafficking;Trauma;United States;Work

PROJECT_TITLE: Metabolic and purinergic immune regulation

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-CB-J(55)R]


NIH_SPENDING_CATS: Biotechnology;Cancer;Cancer Genomics;Clinical Research;Genetic Testing;Genetics;Human Genome;Precision Medicine;Prevention;Urologic Diseases

ORG_CITY: STANFORD

ORG_DEPT: RADIATION-DIAGNOSTIC/ONCOLOGY

ORG_NAME: STANFORD UNIVERSITY

PHR: PROJECT NARRATIVE In this study we will develop and apply novel biomarkers for detecting bladder cancer and for monitoring how bladder cancer patients respond to different treatments. Our long-term objective is to personalize detection and treatment of bladder cancer using these biomarkers in order to maximize cure rates and minimize side effects.

PI_NAMEs: ALIZADEH, ASH ARASH;DIEHN, MAXIMILIAN  (contact);LIAO, JOSEPH C

PROGRAM_OFFICER_NAME: MCKEE, TAWNYA C

PROJECT_TERMS: Address;Adjuvant Chemotherapy;Aftercare;Bacillus Calmette-Guerin Therapy;BCG Live;Biological;Biological Assay;Biological Markers;biomarker panel;Blood;burden of illness;Cancer Detection;Cancer Diagnostics;Cancer Patient;Cancer Personalized Profiling by Deep Sequencing;cancer type;Cells;Cessation of life;Clinical;Clinical Research;Clinical Trials;Clinical Trials Design;cohort;Cystectomy;Cystoscopy;Cytology;Data;Decision Making;design;Detection;detection method;Detection of Minimal Residual Disease;Development;Diagnosis;Diagnostic;Diagnostic Sensitivity;diagnostic strategy;diagnostic tool;Disease;Distant;DNA;DNA analysis;DNA Methylation;DNA Sequence Alteration;Doctor of Philosophy;Early Diagnosis;Early identification;experience;Foundations;Goals;Hematuria;high risk;High-Throughput Nucleotide Sequencing;improved;improved outcome;In complete remission;intravesical;Liquid substance;Malignant neoplasm of urinary bladder;Malignant Neoplasms;Measurement;Medical Oncologist;Methods;Methylation;Molecular;molecular diagnostics;molecular marker;Monitor;muscle invasive bladder cancer;mutant;Neoadjuvant Therapy;non-muscle invasive bladder cancer;novel;novel marker;novel strategies;nucleic acid detection;Nucleic Acids;Oncologist;Pathologic;patient stratification;Patients;Performance;personalized approach;personalized medicine;personalized therapeutic;Physicians;Prediction of Response to Therapy;prospective;Radiation Oncologist;Radical Cystectomy;Recurrence;Research;Research Design;Research Personnel;Residual state;response;Risk;risk prediction;risk stratification;RNA;RNA methylation;Scientist;screening;Sensitivity and Specificity;side effect;Solid;Source;Specificity;Testing;Transurethral Resection;treatment response;treatment strategy;trial design;tumor;tumor DNA;Tumor-Derived;urinary;Urine;Urogenital Cancer;urologic;Urologic Surgeon;Work

PROJECT_TITLE: Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer

STUDY_SECTION: CBSS

STUDY_SECTION_NAME: Cancer Biomarkers Study Section[CBSS]


ORG_NAME: NEW YORK BLOOD CENTER

PHR: Overall Narrative This Program Project will probe the mechanisms underlying the beneficial and harmful effects of transfusions (RBC) in patients with hemoglobinopathies, including patients with sickle cell disease. Focusing on key immune effector cells and cells in the bone marrow, we will evaluate at the cellular level the impact of hemolysis on transfusion outcome on complications ranging from alloimmunization and infections to sickle acute chest syndrome and potentially those affecting hematopoietic transplant outcomes.

PI_NAMEs: YAZDANBAKHSH, KARINA  (contact)

PROGRAM_OFFICER_NAME: YABE, IDALIA MONTANO

PROJECT_TERMS: Acute;acute chest syndrome;Affect;Alloimmunization;Anemia;Anti-Inflammatory Agents;B cell differentiation;B-Cell Development;B-Lymphocytes;Babesia;Babesiosis;Binding;Biological;Bone Marrow;cell type;Cells;CFU-E;Chronic;Clinical;clinical application;Collaborations;Communication;comparison control;Data;Defect;Development;Disease;disease model;Effectiveness;Effector Cell;Erythroblasts;Erythrocyte Transfusion;Erythrocytes;Erythroid;Erythropoiesis;Exhibits;Exposure to;extracellular vesicles;Functional disorder;Goals;Hematopoietic;hematopoietic stem cell niche;hematopoietic transplantation;Heme;heme 1;Hemoglobin;Hemoglobinopathies;Hemolysis;Hemolysis Inhibition;Hemolytic Anemia;HIF1A gene;Human;human subject;Immune;Immune response;Impairment;improved;In Vitro;in vivo Model;Infection;infection rate;Infectious Agent;Inflammation;Inflammatory;inflammatory milieu;Innate Immune Response;insight;Iron;iron metabolism;Island;Knowledge;Life;Lung;Macrophage;Mediator;Mesenchymal Stem Cells;Metabolic;Metabolic Pathway;metabolome;Methods;Molecular;Monitor;mouse model;multidisciplinary;Mus;Outcome;Output;Oxidative Stress;Pathway interactions;patient population;Patients;Phenotype;Play;prevent;Prevention;Productivity;progenitor;programs;Protocols documentation;Quinine;Reaction;Regulation;Research Project Grants;response;Risk;Role;Sampling;Seminal;Sickle Cell;Sickle Cell Anemia;sickling;Signal Transduction;small molecule;Sputum;synergism;T-Lymphocyte;T-Lymphocyte Subsets;targeted agent;Testing;Transfusion;uptake;vascular endothelial dysfunction;Viscosity

PROJECT_TITLE: Complications of Hemolysis and Transfusion Therapy


PROJECT_TERMS: Accounting;Adherence;Administrator;Authorization documentation;Budgets;Charge;Communication;Doctor of Philosophy;Ensure;Expenditure;Financial Support;Fostering;Future;Goals;Grant;Guidelines;Hemolysis;high standard;human subject;IACUC;Individual;Institution;Institutional Review Boards;Joints;Maintenance;Medical center;meetings;member;Monitor;National Heart, Lung, and Blood Institute;Nature;Occupational activity of managing finances;Periodicals;Program Development;programs;Reagent;Regulation;Reporting;Research;Research Personnel;Resource Allocation;Role;Schedule;Scientist;Series;Supervision;System;Transfusion;United States National Institutes of Health;Vertebrates

PROJECT_TITLE: Admin Core


ORG_NAME: BRIGHAM AND WOMEN'S HOSPITAL

PHR: PROJECT NARRATIVE  PARP-2 is a critical component in androgen receptor signaling through interacting with FOXA1. Selective targeting of PARP-2 blocks the PARP-2/FOXA1 interaction, which in turn inhibits androgen receptor-mediated gene expression and prostate cancer growth. In this project, we will define PARP-2 as a therapeutic target in castration-resistant prostate cancer.

PI_NAMEs: JIA, LI  (contact)

PROGRAM_OFFICER_NAME: KAI, MIHOKO

PROJECT_TERMS: abiraterone;Adenosine Diphosphate Ribose;androgen deprivation therapy;androgen independent prostate cancer;Androgen Receptor;androgen sensitive;androgenic;Androgens;Attenuated;Benign;Biochemical;Biology;Cancer Patient;Castrate sensitive prostate cancer;Chromatin;Clinical;clinical application;clinically relevant;Data;Development;DNA Repair Gene;efficacy testing;Enhancers;enzalutamide;Enzymes;evidence base;Family;Future;Gene Expression;Generations;Genes;Genetic;genetic approach;Genetic Transcription;Genome;genome sequencing;Goals;Growth;improved;inhibitor;Ligand Binding;Ligands;Malignant neoplasm of prostate;Malignant Neoplasms;Measures;Mediating;Messenger RNA;Metastatic Prostate Cancer;Modeling;Molecular;Mutate;Mutation;new therapeutic target;novel;novel therapeutic intervention;Oncogenes;Oncogenic;Pathway interactions;Patients;pharmacologic;Play;Poly(ADP-ribose) Polymerase Inhibitor;Poly(ADP-ribose) Polymerases;Polymers;Pre-Clinical Model;Property;Prostate;prostate cancer cell;prostate cancer model;Prostate Cancer therapy;Proteins;Receptor Activation;Receptor Inhibition;Receptor Signaling;recruit;Reporting;Research;Resistance;RNA Splicing;Role;Site;targeted treatment;Therapeutic;therapeutic target;therapy resistant;Tissues;Transcription Coactivator;transcription factor;tumor;tumor growth;Variant;Work

PROJECT_TITLE: Androgen receptor pathway inhibition through targeting PARP-2 in castration-resistant prostate cancer

STUDY_SECTION_NAME: Mechanisms of Cancer Therapeutics - 2 Study Section[MCT2]


NIH_SPENDING_CATS: Clinical Research;Hematology;Rare Diseases;Sickle Cell Disease

PI_NAMEs: SHI, PATRICIA ANN (contact)

PROJECT_TERMS: Acute;Benign;biobank;Biological;Blood;central database;Characteristics;Clinical;clinical application;Clinical Data;clinical development;clinical material;clinical research site;clinically relevant;cloud based;Code;Collaborations;Collection;Communication;Complex;Computer software;Consent;Data;Data Analyses;Databases;Drops;Eligibility Determination;Enrollment;Ensure;experience;Floor;Freezing;Future;Hematologist;Hematology;Hemoglobinopathies;Hemolysis;Human Resources;human subject;Infrastructure;insight;Institution;interest;Laboratories;Logistics;meetings;mouse model;New York;Notification;participant enrollment;Patient Care;Patient Recruitments;Patients;Persons;Physicians;Positioning Attribute;programs;Quality Control;Research;Research Activity;Research Personnel;Research Project Grants;sample collection;Sampling;Schedule;Sickle Cell Anemia;Specialist;Specimen;Study Subject;Time;Transfusion;transfusion medicine;Update;videoconference;Work

PROJECT_TITLE: Human Subjects Core


PROJECT_TERMS: Affect;Alloimmunization;Antioxidants;B cell differentiation;B Cell Proliferation;B-Cell Activation;B-Cell Development;B-Lymphocyte Subsets;B-Lymphocytes;Biliverdine;Binding;Blood Transfusion;Cell Differentiation process;Cell Physiology;Cells;Chemicals;Coculture Techniques;Data;differential expression;Disease;Drug Targeting;effectiveness testing;efficacy testing;Environment;Equilibrium;Event;Frequencies;Functional disorder;Genetic;Helper-Inducer T-Lymphocyte;Heme;heme a;Hemoglobin;Hemoglobinopathies;Hemolysis;Hemolytic Anemia;Humoral Immunities;Immune;Immune response;immunoregulation;In Vitro;in vivo Model;Inflammatory;inhibitor;Innate Immune Response;insight;Isoantibodies;Life;Mediating;Modality;Molecular;Monitor;mouse model;new therapeutic target;novel;Oxidants;Oxidation-Reduction;Pathway interactions;Patients;Peripheral;peripheral tolerance;Pharmaceutical Preparations;Plasma;plasma cell differentiation;Plasma Cells;Play;potential biomarker;prevent;Prevention strategy;Process;Proliferating;Protocols documentation;Quinine;Reaction;Regulation;Reporting;response;Risk;Risk Factors;Role;Sickle Cell Anemia;Signal Pathway;Signal Transduction;Small Interfering RNA;T cell response;Testing;Thalassemia;Transfusion;Up-Regulation

PROJECT_TITLE: Alloimmunization and Humoral Response to Hemolysis


ADMINISTERING_IC: DA

IC_NAME: NATIONAL INSTITUTE ON DRUG ABUSE

NIH_SPENDING_CATS: Behavioral and Social Science;Drug Abuse (NIDA only);Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Mental Health;Mental Illness;Physical Injury - Accidents and Adverse Effects;Prevention;Social Determinants of Health;Substance Misuse;Suicide;Suicide Prevention;Violence Research

ORG_CITY: CHICAGO

ORG_DEPT: EMERGENCY MEDICINE

ORG_NAME: NORTHWESTERN UNIVERSITY AT CHICAGO

ORG_STATE: IL

PHR: Narrative Substance use and suicidal ideation are strongly correlated, which makes intent difficult for death investigators to classify in fatal drug overdoses. As the national rate of fatal drug overdose continues to rise, many of the deaths ruled unintentional or “undetermined” may in fact be suicide victims. This project will leverage data from death certificate, toxicology, police, and coroner/medical examiner reports to (1) identify which factors are most predictive of intent classification and (2) derive a statistical adjustment to estimate underreported suicide deaths in fatal drug overdoses.

PI_NAMEs: LUNDBERG, ALEXANDER  (contact)

PROGRAM_OFFICER_NAME: KURAMOTO-CRAWFORD, SATOKO JANET

PROJECT_TERMS: Acceleration;Accidents;Autopsy;Catalogs;Cause of Death;Cessation of life;Characteristics;Classification;Communities;Coroner;Coroners and Medical Examiners;County;COVID-19 mortality;COVID-19 pandemic;Data;Data Science;data sharing;Data Sources;Death Certificates;Demography;Development;Drug abuse;Economic Conditions;Economics;Emergency Medicine;Epidemiology;experience;Fatality rate;Feeling suicidal;Forensic Medicine;Fright;Growth;health care availability;Homicide;Illinois;Incidence;Information Systems;innovation;insight;Instruction;Intervention;Investigation;Kentucky;Law Enforcement;Length;Linguistics;Litigation;Mediating;Medical Examiners;Mental Health;Mental Health Services;Methods;Michigan;Modeling;mortality;novel;Overdose;overdose death;Persons;Pharmaceutical Preparations;Philosophy;Physicians;Poisoning;Police;Policies;Population;Prevention;Prevention Research;Prevention strategy;Procedures;Public Health;Reporting;Reproducibility;Research;Research Personnel;Resource Allocation;Role;Sampling;Secure;socioeconomics;Sociology;Source;Statistical Methods;structured data;substance use;suicidal;suicidal morbidity;Suicide;suicide model;suicide mortality;Suicide prevention;suicide rate;suicide victim;System;Technology;Text;Time;Toxicology;Training;trend;United States;Violence

PROJECT_TITLE: Suicidal intent in fatal drug overdoses

STUDY_SECTION: SSPB

STUDY_SECTION_NAME: Social Sciences and Population Studies B Study Section[SSPB]


NIH_SPENDING_CATS: Clinical Research;Emerging Infectious Diseases;Hematology;Infectious Diseases;Rare Diseases;Tickborne Diseases;Vector-Borne Diseases

PI_NAMEs: LOBO, CHERYL ANN (contact)

PROJECT_TERMS: Acceleration;Anemia;Autoantibodies;Babesia;Babesiosis;Binding;Biological Assay;Biology;Blood Vessels;Bone Marrow;Cause of Death;Cell membrane;Cell Physiology;Cells;Chromatin;Collaborations;combat;common symptom;Communicable Diseases;Complement;cytokine;Cytolysis;Data;Defect;Deposition;Developing Countries;Development;diagnostic tool;Erythroblasts;Erythrocytes;Erythroid;Erythroid Progenitor Cells;Erythrophagocytosis;Erythropoiesis;Event;Exhibits;experience;extracellular vesicles;Fatty Acids;fungus;Gene Expression;Generations;Goals;Hemolysis;Human;Immune;immune activation;Impairment;In Vitro;in vivo;Infection;Infectious Agent;Inflammatory;insight;Kinetics;Knockout Mice;Link;Lipids;Macrophage;Malaria;Mechanics;Mediating;Membrane;Membrane Microdomains;MicroRNAs;Modeling;Molecular;monocyte;Morbidity - disease rate;mortality;mouse model;Mus;novel strategies;Osmotic Fragility test;Parasites;Parasitic Diseases;pathogen;Pathogenesis;pathogenic bacteria;Pathology;Pathway interactions;Patients;Phagocytes;Phagocytosis;Phenotype;Physical condensation;Predisposition;Production;progenitor;Property;Proteins;Reagent;response;Role;sample fixation;Sickle Cell;Signal Pathway;success;System;Technology;Testing;Transfusion;transmission process;uptake;Vascular blood supply

PROJECT_TITLE: Hemolytic Complications in Babesia Infections


ADMINISTERING_IC: MD

ED_INST_TYPE: UNIVERSITY-WIDE

IC_NAME: NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES

NIH_SPENDING_CATS: Behavioral and Social Science;Brain Disorders;Clinical Research;Depression;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Maternal Health;Maternal Morbidity and Mortality;Mental Health;Mental Illness;Pediatric;Perinatal Period - Conditions Originating in Perinatal Period;Pregnancy;Social Determinants of Health;Women's Health Research

ORG_CITY: Aurora

ORG_NAME: UNIVERSITY OF COLORADO DENVER

ORG_STATE: CO

PHR: Public Health Relevance Section Cultivating biological, psychological, and social resources during pregnancy and throughout the postpartum period is vital to preventing perinatal mood disorders. The Mothers Optimizing Resources Everyday (MORE) study will result in a tailored psychosocial resource intervention that targets specific resources and is delivered during specific critical periods to promote perinatal mental health and well-being and reduce the intergenerational transmission of poor health.

PI_NAMEs: FAREWELL, CHARLOTTE VICTORIA (contact)

PROGRAM_OFFICER_NAME: LINARES, DEBORAH ELIZABETH

PROJECT_TERMS: Address;Adherence;Adult;advanced analytics;Anxiety;Anxiety Disorders;Award;behavioral health;behavioral health intervention;Birth;Buffers;Capital;career;career development;Caring;Child;Clinical;Colorado;Community Health;community setting;coping;Coping Behavior;cost efficient;critical period;Data;Data Analytics;data integration;Depressive disorder;Development;Development Plans;Disparity;disparity reduction;dissemination science;Dose;Economic Factors;Economically Deprived Population;efficacy study;Emotional;Employee;ethnic minority population;evidence base;Evidence based intervention;exhaustion;experience;First Pregnancy Trimester;Fostering;Goals;Growth;Health;health equity;health inequalities;implementation science;improved;Individual;Inequity;innovation;intergenerational;Intervention;Interview;Life;Life Cycle Stages;longitudinal analysis;low socioeconomic status;Maintenance;Measurable;Mental Depression;Mental Health;Mental health promotion;Modality;Modeling;Mood Disorders;motherhood;Mothers;National Institute on Minority Health and Health Disparities;optimism;Outcome;perceived stress;Perinatal;perinatal intervention;perinatal mental health;perinatal period;peripartum depression;Personal Satisfaction;Phase;Population;Postpartum Period;Pregnancy;pregnant;prenatal;Prevention;Process;professor;programs;protective factors;prototype;psychologic;Psychological adjustment;psychosocial;Public Health Schools;racial minority population;Reporting;Research;resilience;Resource-limited setting;Resources;Role;satisfaction;Science;Scientist;Self Efficacy;skills;social;social capital;social factors;social stigma;Social support;socioeconomic disadvantage;socioeconomic disparity;Socioeconomic Status;Stress;Stress and Coping;Structure;Students;Subgroup;Testing;Third Pregnancy Trimester;Time;Training;transmission process;United States National Institutes of Health

PROJECT_TITLE: Mothers Optimizing Resources Everyday (MORE): Buffering mental health inequities in low-resourced perinatal populations


NIH_SPENDING_CATS: Biotechnology;Clinical Research;Genetics;Hematology;Rare Diseases;Regenerative Medicine;Sickle Cell Disease;Stem Cell Research;Stem Cell Research - Nonembryonic - Non-Human;Transplantation

PI_NAMEs: AN, XIULI  (contact)

PROJECT_TERMS: Acute;Adhesives;Affect;Anemia;Antibodies;Apoptosis;Bone Marrow;Bone Marrow Diseases;bone marrow mesenchymal stem cell;Cell Adhesion Molecules;Cell Maintenance;Cell Nucleus;Cell Proliferation;Cells;CFU-E;Chromatin;Chronic;Data;Development;Disease;DNA Damage;EPOR gene;Erythroblasts;Erythroid;Erythroid Cells;erythroid differentiation;Erythropoiesis;Functional disorder;functional improvement;Gamma-H2AX;Gene Expression;gene therapy;Generations;Glutamine;healthcare burden;Hematopoiesis;Hematopoietic;hematopoietic differentiation;hematopoietic stem cell niche;Hematopoietic Stem Cell Transplantation;Hematopoietic stem cells;Heme;Hemolysis;Hemolysis Induction;Hemopexin;Homeostasis;Human;hydroxyurea;Impairment;improved;In Vitro;in vivo;Inflammatory;interest;Island;Knock-in Mouse;Macrophage;Mediating;Membrane Lipids;Membrane Microdomains;Mesenchymal Stem Cells;Methods;Modeling;Molecular;mouse model;Mus;Nature;new therapeutic target;novel;novel therapeutic intervention;Patients;peripheral blood;Physical condensation;Platelet-Derived Growth Factor alpha Receptor;Play;Process;Production;progenitor;Proliferating;Property;reconstitution;Reporting;Role;Sickle Cell Anemia;Signal Transduction;stem cells;Stress;Stromal Cells;Testing;Therapeutic;transcriptome sequencing;Transfusion;Transplantation;transplantation therapy;Validation;Wild Type Mouse

PROJECT_TITLE: Hemolysis and the Hematopoietic Niche


NIH_SPENDING_CATS: Clinical Research;Emerging Infectious Diseases;Hematology;Infectious Diseases;Lung;Rare Diseases;Sickle Cell Disease

PI_NAMEs: VINCHI, FRANCESCA  (contact)

PROJECT_TERMS: Acute;acute chest syndrome;Address;Adoptive Transfer;Alveolar;Anti-Inflammatory Agents;Antiinflammatory Effect;Autophagocytosis;Babesia;Babesiosis;beta Thalassemia;Blood Vessels;Bone Marrow;Cells;Chronic;Circulation;cytokine;Data;Development;Disease;disease model;Embolism;Equilibrium;Erythrocyte Transfusion;Erythrocytes;Erythrophagocytosis;Event;Exposure to;Fatty acid glycerol esters;Functional disorder;Goals;Heme;Hemolysis;Hepatic;HIF1A gene;improved;Infection;Inflammation;Inflammatory;Inflammatory Response;inhibitor;insight;interstitial;Iron;Island;Lipids;Liver Fibrosis;Lung;Lung infections;lung injury;Macrophage;Macrophage Activation;Mediating;Mediator;Metabolic;Metabolism;metabolome;Molecular;Morbidity - disease rate;mortality;mouse model;Mus;new therapeutic target;NF-kappa B;NFKB Signaling Pathway;novel therapeutic intervention;Outcome;Oxidative Phosphorylation;Pathogenesis;Pathway interactions;Patients;Phagocytes;Phagocytosis;Phagocytosis Induction;Phenotype;Plasma;Population;premature;prevent;Prevention;Property;Publishing;Pulmonary Inflammation;Quinine;response;response to injury;Role;Sickle Cell Anemia;Signal Transduction;Sputum;Stimulus;stressor;Symptoms;Syndrome;synergism;Testing;Therapeutic;Tissues;TRAF6 gene;Transfusion;translational study;Vascular Endothelium;Vesicle

PROJECT_TITLE: Macrophage Functional Response in Hemolytic Complications


ED_INST_TYPE: SCHOOLS OF PHARMACY

ORG_CITY: HOUSTON

ORG_DEPT: PHARMACOLOGY

ORG_NAME: UNIVERSITY OF HOUSTON

ORG_STATE: TX

PHR: Project Narrative: Endothelial dysfunction refers to the loss of normal protective function of endothelial cells that locate within the inner layer of arteries. This grant application for the first time explores a tonic regulation of sphingolipid metabolism in endothelial cells by an enzyme that usually modifies the chromosomal DNA and how such regulation contributes to obesity-induced endothelial dysfunction and thereby provokes vascular injury and artery hardening. Our findings will answer an important question of how vascular injury and artery hardening start within cells at the very early stage of patients with cardiovascular risk factor such as hyperlipidemia and obesity and will help develop new strategies for treatment and prevention of vascular injury and artery hardening in these patients.

PI_NAMEs: LI, XIANG  (contact)

PROGRAM_OFFICER_NAME: GAO, YUNLING

PROJECT_TERMS: 7-ketocholesterol;Abbreviations;acid sphingomyelinase;Adhesions;Applications Grants;arterial stiffness;Arteries;Atherosclerosis;Blood Vessels;cardiovascular risk factor;Cardiovascular system;Carotid Arteries;CASP1 gene;Cell membrane;Cells;Ceramide Signaling Pathway;Ceramides;Defect;Development;Diabetes Mellitus;DNA;DNA Methylation;DNA Modification Methylases;Endothelial Cells;endothelial dysfunction;endothelial stem cell;Endothelium;Enhancers;Enzymes;Epigenetic Process;epigenetic regulation;Gene Expression;Genes;High Fat Diet;histone methylation;histone methyltransferase;Homologous Gene;Human;Hydrolysis;Hyperlipidemia;Hypertension;IL18 gene;Immunohistochemistry;Impairment;Inflammasome;Inflammatory Response;Injury;insight;Interleukin-1 beta;Knock-out;Knockout Mice;Lesion;marenostrin;Mediating;Membrane;Metabolic;Metabolism;Methylation;Molecular;monocyte;Morbidity - disease rate;mortality;Mus;Nonesterified Fatty Acids;novel;novel therapeutic intervention;Nucleotides;Obesity;obesity development;Oxidation-Reduction;Palmitates;Pathogenesis;Pathologic;Pathway interactions;Patients;Pattern;Phenotype;Prevention;Production;Proteins;Reactive Oxygen Species;receptor;Regulation;Role;Signal Pathway;Signal Transduction;Signaling Molecule;Smooth Muscle;Smooth Muscle Myocytes;Sphingolipids;Sphingomyelins;Testing;therapeutic target;Time;Transcriptional Regulation;Umbilical vein;Vascular Diseases;vascular injury;Vasodilation

PROJECT_TITLE: Enhancer of zeste homolog 2-mediated epigenetic activation of acid sphingomyelinase in endothelial dysfunction during obesity

STUDY_SECTION: HM

STUDY_SECTION_NAME: Hypertension and Microcirculation Study Section[HM]


NIH_SPENDING_CATS: Cancer;Childhood Leukemia;Clinical Research;Hematology;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

ORG_CITY: ROCHESTER

ORG_NAME: MAYO CLINIC ROCHESTER

ORG_STATE: MN

PHR: NARRATIVE Over 50% of patients who develop acute myeloid leukemia (AML) will die of this disease. While the development of targeted therapies has improved the outcome for some patients with this disease, these targeted therapies are usually administered in conjunction with conventional cytotoxic agents. Many of these conventional antileukemic drugs induce DNA-protein crosslinks, a type of DNA damage that has previously been difficult to measure. Here we use a recently derived immunological reagent to show that AML cell lines and clinical samples contain a previously unsuspected excess of these DNA-protein crosslinks. In particular, malignant myeloid cells exhibit elevated levels of crosslinks between the nuclear enzyme TOP1 and DNA even before being exposed to TOP1-directed drugs. We now propose to investigate the biochemical basis for the large numbers of pre-existing TOP1-DNA covalent complexes and assess whether the existence of these complexes predicts a favorable response to TOP1-directed anti-leukemic therapy.

PI_NAMEs: KAUFMANN, SCOTT H (contact)

PROGRAM_OFFICER_NAME: OLKHANUD, PUREVDORJ BALJINNYAM

PROJECT_TERMS: Acute Lymphocytic Leukemia;Acute Myelocytic Leukemia;acute myeloid leukemia cell;Affect;Age;Anthracycline;Antibodies;antileukemic agent;Azacitidine;Binding;Biochemical;Camptothecin;Cancer Therapy Evaluation Program;Case Fatality Rates;Cell Line;cell type;Cells;chromatin protein;Chronic Myelomonocytic Leukemia;Clinic;Clinical;Collaborations;comorbidity;Complex;covalent bond;crosslink;Cytotoxic agent;Daunorubicin;Decitabine;Defect;design;Development;Disease;DNA;DNA Damage;DNA lesion;DNA Methyltransferase Inhibitor;DNA Modification Methylases;DNA Topoisomerases;DNA-protein crosslink;drug sensitivity;Drug usage;Dysmyelopoietic Syndromes;Enzymes;Etoposide;Excision;Exhibits;Exposure to;Formaldehyde;Generations;Hematopoietic;Hematopoietic Stem Cell Transplantation;Hemorrhagic Thrombocythemia;high reward;high risk;histone demethylase;Human;Immunologics;improved;improved outcome;In Vitro;in vivo;in vivo Model;insight;Knock-out;Lead;Lesion;leukemia;leukemia treatment;Leukemic Cell;Lymphoid Cell;Malignant - descriptor;Marrow;Measures;Metabolism;Metalloproteases;Mitoxantrone;Myeloid Cells;Myeloid Leukemia;Myeloproliferative disease;Nuclear;nuclease;Participant;Pathway interactions;Patients;Peptide Hydrolases;Pharmaceutical Preparations;Pharmacotherapy;Phase;phase II trial;phosphoric diester hydrolase;Play;Poison;Polycythemia Vera;Process;progenitor;prototype;Reagent;Regimen;Repair Complex;repaired;Reporting;research clinical testing;response;Role;Sampling;Serine Protease;Specimen;Stabilizing Agents;Syndrome;targeted agent;targeted treatment;Testing;Therapeutic;Tissues;TOP1 gene;TOP2A gene;Topoisomerase;Topotecan

PROJECT_TITLE: Cause and therapeutic impact of DNA-protein crosslink repair defect in myeloid leukemias


FUNDING_MECHANISM: TRAINING, INSTITUTIONAL

NIH_SPENDING_CATS: Cancer

PHR: PROJECT NARRATIVE Cancer diagnosis and treatment has become much more complex over the past several years. We propose a continuing a training program using the considerable resources of Columbia University Irving Medical Center to provide cancer physicians of outstanding promise the tools and skills that will be needed to make key discoveries and to develop productive research careers in academic medicine.

PI_NAMEs: CREW, KATHERINE D;HERSHMAN, DAWN  (contact);MAPARA, MARKUS Y

PROGRAM_OFFICER_NAME: LIM, SUSAN E

PROJECT_TERMS: molecular oncology;Training Programs

PROJECT_TITLE: Molecular Oncology Training Program


NIH_SPENDING_CATS: Aging;Cardiovascular;Heart Disease;Heart Disease - Coronary Heart Disease;Hematology;Regenerative Medicine;Stem Cell Research;Stem Cell Research - Nonembryonic - Non-Human

ORG_CITY: TAMPA

ORG_DEPT: PHYSIOLOGY

ORG_NAME: UNIVERSITY OF SOUTH FLORIDA

ORG_STATE: FL

PHR: PROJECT NARRATIVE Over one million Americans each year are diagnosed with myocardial infarction (MI), of which around 25% will continue to remodel and develop chronic heart failure. The goals of this proposal are to elucidate the molecular mechanisms that cause post-MI T lymphopenia (a decrease in peripheral blood T-cell count) and to investigate whether preventing CD4+ T lymphopenia can serve as a therapeutic strategy. Accomplishment of this proposal will likely provide a potential intervention strategy to improve cardiac repair in ischemic heart failure.

PI_NAMEs: MA, YONGGANG  (contact)

PROGRAM_OFFICER_NAME: SCHWARTZ, LISA

PROJECT_TERMS: Acute myocardial infarction;Adoptive Transfer;Affect;American;Apoptosis;Blood;Bone Marrow;cardiac repair;CD4 Positive T Lymphocytes;CD8-Positive T-Lymphocytes;CD8B1 gene;Cell Count;Cell Lineage;Cell Physiology;cell type;Chemotaxis;Clinical Research;Congestive Heart Failure;CXCR4 gene;Data;Death Rate;Deterioration;Diagnosis;Glucocorticoid Receptor;Glucocorticoids;Goals;heart damage;Heart failure;heart function;Hematopoietic stem cells;Impairment;improved;insight;interdisciplinary approach;Intervention;Lymphocyte Count;Lymphoid;Lymphopenia;Lymphopoiesis;Mediating;Modeling;Molecular;Morbidity - disease rate;mortality;Mus;Myelopoiesis;Myocardial;Myocardial Infarction;Myocardial Ischemia;novel;Outcome;Patients;peripheral blood;Peripheral Blood Lymphocyte;Phenotype;Physiological Processes;Play;premature;prevent;progenitor;Prognosis;Proliferating;PTPRC gene;repaired;Reperfusion Therapy;response;Risk;Role;side effect;Signal Transduction;stem cells;Stromal Cell-Derived Factor 1;T cell response;T memory cell;T-Cell Activation;T-Cell Development;T-Lymphocyte;Therapeutic;thymocyte;Thymus Gland;tool;trafficking;Travel;United States;wound healing

PROJECT_TITLE: T Lymphopenia in Ischemic Heart Failure

STUDY_SECTION: MPPA

STUDY_SECTION_NAME: Integrative Myocardial Physiology/Pathophysiology A Study Section [MPPA]


NIH_SPENDING_CATS: Behavioral and Social Science;Cardiovascular;Clinical Research;Clinical Trials and Supportive Activities;Heart Disease;Physical Activity;Prevention

ORG_CITY: MANHASSET

ORG_NAME: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH

PHR: Millions of American adults are at risk for developing cardiovascular disease (CVD). Scientists have shown that even people who only engage in low intensity physical activities, like walking, can lessen their risk for developing CVD. This study will test four different types of behavior change techniques to see which one(s) help people who are not active to walk more each day. Study participants will wear a research activity tracker called an ActiGraph, receive text messages about walking and answer some survey questions each month.

PI_NAMEs: DAVIDSON, KARINA W. (contact)

PROGRAM_OFFICER_NAME: CAMPO, REBECCA A

PROJECT_TERMS: Accelerometer;actigraphy;Address;Adherence;Adult;aged;American;arm;Basic Science;Behavior;behavior change;behavior influence;Behavioral;Behavioral Mechanisms;Cardiovascular Diseases;cardiovascular disorder prevention;cardiovascular disorder risk;Cells;Communities;cost;Counseling;design;Eligibility Determination;eligible participant;exercise intervention;Experimental Designs;experimental study;Feedback;Future;Goals;Guidelines;Health behavior;improved;Individual;innovation;Intervention;Knowledge;Mediating;Mediation;Mediator;Medicine;Methods;Modality;Modeling;moderate-to-vigorous physical activity;Monitor;Morbidity - disease rate;mortality;older adult;Outcome;Participant;Persons;Physical activity;Play;Populations at Risk;prevent;Program Sustainability;Public Health;Publishing;Randomized;Randomized, Controlled Trials;Recommendation;recruit;remote delivery;Research;Research Activity;Research Personnel;Risk;Risk Factors;Role;Science;Scientist;sedentary;sedentary lifestyle;Self Efficacy;Surveys;systematic review;Techniques;Testing;Text;Text Messaging;theories;therapy development;Time;Walking

PROJECT_TITLE: Influencing Basic Behavioral Mechanisms of Action while targeting Daily Walking in Those at Risk for Cardiovascular Disease: Science of Behavior Change Factorial Experiment of Behavioral Change

STUDY_SECTION: BMIO

STUDY_SECTION_NAME: Behavioral Medicine, Interventions and Outcomes Study Section[BMIO]


ADMINISTERING_IC: AA

ED_INST_TYPE: SCHOOLS OF PUBLIC HEALTH

IC_NAME: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

NIH_SPENDING_CATS: Alcoholism, Alcohol Use and Health;Behavioral and Social Science;Childhood Injury;Pediatric;Physical Injury - Accidents and Adverse Effects;Prevention;Social Determinants of Health;Substance Misuse;Underage Drinking;Violence Against Women;Violence Research;Women's Health Research;Youth Violence;Youth Violence Prevention

ORG_CITY: PITTSBURGH

ORG_DEPT: PUBLIC HEALTH & PREV MEDICINE

ORG_NAME: UNIVERSITY OF PITTSBURGH AT PITTSBURGH

PHR: PROJECT NARRATIVE Alcohol-involved sexual violence on college campuses may best be addressed through a combination of campus policies and programs, behavioral interventions, and community-level interventions. We will use stakeholder-designed models to create tools to optimize hazardous drinking and sexual violence interventions on college campuses. These efforts will improve implementation of effective strategies, promote prevention strategies among students, and stimulate campus-level policy changes.

PI_NAMEs: MAIR, CHRISTINA FURBER (contact)

PROGRAM_OFFICER_NAME: FREEMAN, ROBERT

PROJECT_TERMS: Address;Alcohol abuse;Alcohol consumption;alcohol involvement;Attention;Back;Behavior;Behavior Therapy;Behavioral;Biological Models;brief intervention;Climate;college;Communities;community intervention;Complex;Counseling;design;Development;drinking;Education;Environment;Epidemiology;Feedback;Female;Foundations;Goals;Greek;hazardous drinking;Health;implementation intervention;improved;Individual;innovation;Intervention;Learning;Methodology;Methods;model building;model design;model development;Modeling;neglect;Output;Pennsylvania;Persons;Policies;Population;Prevention approach;Prevention strategy;preventive intervention;Process;Professional counselor;programs;Public Health;Recording of previous events;recruit;Reporting;Risk;Science;Series;sexual assault;sexual violence;Sexual violence prevention;simulation;social;Students;success;support tools;Surveys;System;Title IX;tool;Training;Translating;undergraduate student;West Virginia

PROJECT_TITLE: Collaborator-designed agent-based models to inform alcohol-involved sexual violence prevention on college campuses.

STUDY_SECTION: CIHB

STUDY_SECTION_NAME: Community Influences on Health Behavior Study Section[CIHB]


ORG_CITY: NEW HAVEN

ORG_NAME: YALE UNIVERSITY

ORG_STATE: CT

PHR: The goal of this postdoctoral training program is to train future leaders, from diverse backgrounds, in areas of vascular biology and cardiovascular research. Heart disease is the leading cause of death in the U.S., and as such, defining the causes and mechanisms of disease continues to be of great significance. This training program, through its mentoring of future leaders in cardiovascular research, will have an important impact on health in the U.S.

PI_NAMEs: BENDER, JEFFREY R. (contact);CHUN, HYUNG JOON

PROGRAM_OFFICER_NAME: LIDMAN, KARIN FREDRIKSSON

PROJECT_TERMS: Blood Vessels;Grant;Training

PROJECT_TITLE: Vascular Training Grant

STUDY_SECTION: NITM

STUDY_SECTION_NAME: NHLBI Institutional Training Mechanism Study Section[NITM(OA)]


ED_INST_TYPE: BIOMED ENGR/COL ENGR/ENGR STA

NIH_SPENDING_CATS: Bioengineering;Biotechnology;Cancer;Cancer Genomics;Clinical Research;Colorectal Cancer;Digestive Diseases;Genetics;Human Genome;Obesity;Regenerative Medicine

ORG_CITY: Auburn

ORG_DEPT: ENGINEERING (ALL TYPES)

ORG_NAME: AUBURN UNIVERSITY AT AUBURN

ORG_STATE: AL

PHR: Project Narrative The tissue engineered platforms developed and validated in the proposed project will be extremely valuable to the understanding and eventual treatment of colorectal cancer (CRC) linked to obesity. The portability of these tissue engineered platforms to other obesity-linked cancers and cancer in general has the potential to inform and shift current research and clinical practice.

PI_NAMEs: GREENE, MICHAEL W;LIPKE, ELIZABETH A (contact)

PROGRAM_OFFICER_NAME: BECKER, STEVEN

PROJECT_TERMS: 3-Dimensional;Adipocytes;Adipose tissue;Affect;anti-cancer research;Beds;Benchmarking;Bioinformatics;bioinformatics tool;Biological Assay;Biomimetics;cancer cell;Cancer Model;cancer subtypes;Cell Line;Cells;Clinical Data;Clinical Oncology;clinical practice;Coculture Techniques;cohort;Colon Adenocarcinoma;colon cancer patients;Colon Carcinoma;Colorectal Cancer;colorectal cancer treatment;Complex;Conditioned Culture Media;Consensus;Cues;Disease;Disease Progression;Engineering;Epidemiology;Extracellular Matrix;flexibility;Gene Expression;Genomics;Growth;Heterogeneity;Human;Implant;improved;In Vitro;in vitro Model;in vivo;in vivo Model;Infiltration;Inflammation;Inflammatory;Insulin Resistance;Investigator-Initiated Research;Link;Maintenance;Malignant Neoplasms;Mechanics;Mediating;Metabolic;Metabolic Diseases;model development;Modeling;molecular subtypes;Morbidity - disease rate;mortality;Mus;Obesity;Pathologic;Pathway interactions;patient derived xenograft model;Patients;Phenotype;Population;portability;primary outcome;Proliferating;Property;Proteomics;Research;response;Role;Signal Pathway;Signal Transduction;skills;Stromal Cells;systemic inflammatory response;Technology;Testing;The Cancer Genome Atlas;Thinness;tissue culture;Tissue Engineering;Tissues;tool;transcriptome sequencing;transcriptomics;Transforming Growth Factor beta;Transplantation;tumor;Tumor Bank;tumor growth;tumor microenvironment;tumor progression;tumor xenograft;Validation

PROJECT_TITLE: Engineered Colon Cancer Tissue to Examine the Role of the Obese Microenvironment in Tumor Aggressiveness

STUDY_SECTION: CMT

STUDY_SECTION_NAME: Cellular and Molecular Technologies Study Section[CMT]


ORG_CITY: CHARLESTON

ORG_DEPT: BIOCHEMISTRY

ORG_NAME: MEDICAL UNIVERSITY OF SOUTH CAROLINA

ORG_STATE: SC

PHR: PROJECT NARRATIVE Despite the tremendous progress that has been achieved in understanding the complex biology of cancer over the past several decades, it remains a major health care challenge and requires a highly trained work force to continue to develop new, more effective therapeutic approaches. The Hollings Cancer Center at the Medical University of South Carolina seeks continued funding for its Integrative Training in Oncogenic Signaling (ITOS) Program. This Program is led by a specialized group of core scientists who provide a structured, integrated training experience to ensure the next generation is equipped with contemporary, interdisciplinary approaches and technical expertise that will eventually overcome the challenges to this disease.

PI_NAMEs: HOWE, PHILIP H (contact)

PROJECT_TERMS: Oncogenic;Signal Transduction;Training


FUNDING_MECHANISM: TRAINING, INDIVIDUAL

NIH_SPENDING_CATS: Cancer;Genetics

ORG_CITY: PHILADELPHIA

ORG_NAME: UNIVERSITY OF PENNSYLVANIA

PHR: Project Narrative The centromere, the chromosomal locus at which the kinetochore protein complex assembles and mediates attachments to spindle microtubules, is essential for proper segregation of chromosomes and therefore faithful propagation of genetic information across cell and organismal generations. Aberrant chromosome segregation contributes to cancer progression, leads to developmental defects, and activates anti-tumor inflammatory responses. This application proposes to obtain the first in situ structures of the centromere and kinetochore and to answer fundamental questions about the protein interactions required for essential centromere functions.

PI_NAMEs: KIXMOELLER, KATHRYN  (contact)

PROGRAM_OFFICER_NAME: DAMICO, MARK W

PROJECT_TERMS: Antineoplastic Agents;Area;Auxins;Binding;Biological Assay;Biology;Black race;cancer cell;Cell Cycle;Cell Cycle Stage;Cell Death;Cell division;Cells;Cellular biology;Centromere;centromere protein A;centromere protein C;Chromatin;Chromosome abnormality;chromosome missegregation;Chromosome Segregation;Chromosomes;Complex;Cryo-electron tomography;Defect;Deposition;design;Development;Disease;Elements;Emerging Technologies;Epigenetic Process;experimental study;Foundations;G1 Phase;gene product;Generations;genetic information;genomic locus;Genomics;Health;Histone H3;Histones;Human;Hydration status;In Situ;In Vitro;in vivo;Inflammatory Response;Infrastructure;insight;Interphase;Interphase Cell;Kinetochores;Maintenance;Malignant Neoplasms;Maps;Mediating;Metaphase;Methods;Microtubules;Mitosis;Mitotic spindle;Modeling;Molecular Machines;Mutagenesis;N-terminal;Nature;Nucleosomes;Pennsylvania;Process;protein complex;Proteins;reconstitution;Research;Role;segregation;Small Interfering RNA;stoichiometry;Structure;Testing;transmission process;tumor;tumor progression;Uncertainty;Universities;Variant;Weight-Bearing state;Work

PROJECT_TITLE: Investigating the structure and function of the human centromere and kinetochore

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-F08-M(20)L]


NIH_SPENDING_CATS: Biotechnology;Cancer;Cancer Genomics;Genetics;Hematology;Human Genome;Immunotherapy;Lymphatic Research;Lymphoma;Orphan Drug;Rare Diseases

ORG_CITY: DUARTE

ORG_NAME: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE

PHR: Project Narrative This proposal focuses on the molecular mechanisms by which CEACAM1 promotes important survival signals in mantle cell lymphoma and on the pre-clinical evaluation of CEACAM1 as a novel immunotherapeutic target. Results from these studies are expected to improve our understanding of abnormal signaling pathways underlying lymphoma development and to provide new insights for novel, effective therapeutic interventions.

PI_NAMEs: NGO, VU NGUYEN (contact)

PROGRAM_OFFICER_NAME: JHAPPAN, CHAMELLI

PROJECT_TERMS: Actin-Binding Protein;Actins;Activated Lymphocyte;Adhesions;Antibody Therapy;Antigens;Automobile Driving;autoreactive B cell;B lymphoid malignancy;B-Cell Activation;B-Cell Antigen Receptor;B-Cell Lymphomas;B-Lymphocytes;CCND1 gene;CEACAM1;Cell membrane;cell type;Cells;chimeric antigen receptor;chimeric antigen receptor T cells;Chronic Lymphocytic Leukemia;Cities;Clinical;Clinical Trials;Collaborations;Confocal Microscopy;CRISPR library;crosslink;Cytoplasmic Tail;Cytoskeleton;Data;design;Development;Ectopic Expression;effective therapy;efficacy testing;Engineering;Experimental Genetics;Family;filamin;Gene Expression Profiling;Genetic;genome-wide;Human;IGH@ gene cluster;Immunotherapeutic agent;Immunotherapy;improved;In Vitro;in vivo;in vivo Model;insight;Integral Membrane Protein;ITIM;large cell Diffuse non-Hodgkin's lymphoma;Lymphoma;Lymphoma cell;LYN gene;Mantle Cell Lymphoma;medical schools;Membrane;Membrane Microdomains;Molecular;mouse model;Mus;Mutate;new therapeutic target;Non-Hodgkin's Lymphoma;novel;NR0B2 gene;Oncogenic;overexpression;Pathway interactions;Patients;Pharmaceutical Preparations;Phosphoric Monoester Hydrolases;Phosphotransferases;pre-clinical;preclinical evaluation;Prognosis;Proliferating;Protein Tyrosine Kinase;PTPRC gene;Receptor Signaling;recruit;Refractory;Resistance;Resistance development;Role;Safety;safety testing;Signal Pathway;Signal Transduction;small molecule inhibitor;Somatic Mutation;SOX11 gene;Specificity;standard of care;Surface;T-Cell Receptor;T-Lymphocyte;Testing;Therapeutic;Therapeutic Intervention;therapeutic target;therapeutically effective;Transgenic Mice;tumor;ultra high resolution;Validation;Xenograft procedure

PROJECT_TITLE: The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-OTC-M(08)F]


NIH_SPENDING_CATS: Alcoholism, Alcohol Use and Health;Basic Behavioral and Social Science;Behavioral and Social Science;Neurosciences;Substance Misuse

ORG_CITY: AUSTIN

ORG_DEPT: NEUROLOGY

ORG_NAME: UNIVERSITY OF TEXAS AT AUSTIN

PHR: PROJECT NARRATIVE These studies will investigate the role of phosphodiesterase 4 (PDE4) enzymes and GABAA receptor beta subunits in alcohol tolerance and alcohol consumption. These studies hope to identify a specific PDE4 and a specific subunit of GABAA receptors as drug targets for treatment of alcohol use disorder.

PI_NAMEs: MESSING, ROBERT O. (contact)

PROGRAM_OFFICER_NAME: LIU, QI-YING

PROJECT_TERMS: Acute;alcohol behavior;Alcohol consumption;alcohol response;alcohol reward;alcohol use disorder;Alcohols;Animals;Antibodies;Ataxia;Behavior;Behavioral;Blood alcohol level measurement;Brain;Complex;Consumption;Cyclic AMP;Cyclic AMP-Dependent Protein Kinases;Development;Disincentive;Dose;drinking;Enzymes;Ethanol;Ethanol Metabolism;experimental study;GABA-A Receptor;Goals;Hippocampus;Immunoprecipitation;Impairment;improved;inhibitor;interest;Intoxication;Isoenzymes;Knock-in Mouse;Knockout Mice;Mass Spectrum Analysis;Mediating;Metabolism;Minor;Mus;Mutate;Mutation;novel;Oocytes;PDE4B;Persons;Pharmaceutical Preparations;Pharmacodynamics;Phosphodiesterase Inhibitors;phosphodiesterase IV;Phosphorylation;Phosphorylation Site;positive allosteric modulator;prevent;Property;protein activation;Protein Isoforms;Proteins;receptor;receptor function;Regulation;response;Risk Factors;Rodent;Role;Series;side effect;Slice;targeted treatment;Testing;Wild Type Mouse;Work;Xenopus laevis;Xenopus oocyte

PROJECT_TITLE: PDE4 regulation of GABA-A receptors in alcohol tolerance and consumption

STUDY_SECTION: NAL

STUDY_SECTION_NAME: Neurotoxicology and Alcohol Study Section[NAL]


ED_INST_TYPE: SCHOOL OF MEDICINE & DENTISTRY

NIH_SPENDING_CATS: Assistive Technology;Bioengineering;Cardiovascular;Clinical Research;Clinical Trials and Supportive Activities;Heart Disease;Patient Safety;Prevention

ORG_NAME: UNIVERSITY OF ROCHESTER

PHR: Project Narrative Ventricular tachycardia is a life-threatening heart rhythm disorder that can complicate the course of patients with advanced heart failure and heart assist pumps (left ventricular assist device; LVAD). Ablation can be an effective treatment that modifies that scars in the heart leading to short circuits causing ventricular tachycardia. The goal of this clinical randomized trial is to determine if an intraoperative VT ablation can help reduce ventricular tachyarrhythmias in patients undergoing LVAD implantation.

PI_NAMEs: HUANG, DAVID T (contact)

PROGRAM_OFFICER_NAME: DESVIGNE-NICKENS, PATRICE

PROJECT_TERMS: Ablation;Accounting;Adverse event;adverse outcome;Arrhythmia;Cardiac Catheterization Procedures;Cessation of life;Cicatrix;Clinical;Cohort Studies;comparison control;Control Groups;Data;Devices;Disease;Early Intervention;Echocardiography;effective therapy;Electrophysiology (science);Eligibility Determination;Enrollment;Event;Exercise;experience;Failure;follow-up;Freedom;Generations;Goals;Heart;Heart failure;heart rhythm;Heart-Assist Devices;hemodynamics;high risk;high risk population;hospital readmission;Hospitalization;Implant;implantable device;implantation;improved;innovation;ischemic cardiomyopathy;left ventricular assist device;Life;Maps;Measures;Mechanics;Medical;Medical center;Monitor;mortality;mortality risk;Multi-Institutional Clinical Trial;Myocardial Ischemia;novel strategies;Outcome;Patients;Postoperative Period;preservation;Procedures;prophylactic;prospective;Protocols documentation;Publishing;Ramp;Randomized;randomized, clinical trials;Recording of previous events;Records;Recurrence;right ventricular failure;Risk;Safety;Safety Management;Specific qualifier value;Stress;Stroke;Tachyarrhythmias;Testing;Time;Translating;Universities;Ventricular;Ventricular Tachycardia

PROJECT_TITLE: Prophylactic Intra-Operative VT Ablation in High-Risk LVAD Candidates

STUDY_SECTION: CCHS

STUDY_SECTION_NAME: Clinical Integrative Cardiovascular and Hematological Sciences Study Section[CCHS]


NIH_SPENDING_CATS: Biotechnology;Breast Cancer;Cancer;Prevention;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Women's Health Research

ORG_NAME: BETH ISRAEL DEACONESS MEDICAL CENTER

PHR: PROJECT NARRATIVE  Triple-negative breast cancers (TNBCs) represent an aggressive type of breast cancer with no effective and targeted prognostic and therapeutic strategies. Studies proposed herein are based on preliminary results showing that TNBCs are particularly enriched in a pentraxin called PTX3, which we show is highly associated with experimental and clinical TNBC, is functional in driving several traits of TNBC malignancy in vitro and in vivo, and whose antagonism compromises TNBC cell survival. Here, we seek to establish PTX3 as clinically relevant biomarker, further elucidate its pro-malignant functions, and determine its utility as a therapeutic target using preclinical models, thereby introducing a novel theranostic of potential groundbreaking impact in managing aggressive and difficult-to-treat breast TNBCs.

PI_NAMEs: KARNOUB, ANTOINE ELIAS (contact)

PROGRAM_OFFICER_NAME: DEY, SUMANA MUKHERJEE

PROJECT_TERMS: 3-Dimensional;Anchorage-Independent Growth;Animals;antagonist;Antibodies;Apoptosis;Apoptotic;Automobile Driving;Behavior;Biological Markers;biomarker discovery;Blood;Breast;Breast Cancer Cell;breast cancer metastasis;Breast Cancer Patient;Breast Oncology;cancer cell;Cancer Cell Growth;Cancer Model;Cancer Patient;cancer stem cell;Cell Death;cell growth;Cell secretion;Cell Survival;Chemoresistance;chemotherapy;Circulation;Clinic;Clinical;Clinical Management;clinically relevant;cohort;Complement Activation;desensitization;Disease;Disease Progression;efficacy testing;Enzyme-Linked Immunosorbent Assay;Fostering;Genetic Suppression;Growth;Histopathologic Grade;Human;human disease;In Situ;In Vitro;in vivo;Inhibition of Cancer Cell Growth;innovation;Malignant - descriptor;Malignant Breast Neoplasm;Malignant Neoplasms;Mediating;microorganism antigen;migration;mouse model;Mus;Neoplasm Metastasis;neutralizing antibody;novel;novel marker;Oncogenes;Oncology;Pathogenesis;Pathologic;Pathway interactions;patient derived xenograft model;patient prognosis;Patient-derived xenograft models of breast cancer;Patients;Peripheral;Play;pre-clinical;Pre-Clinical Model;prevent;Prognosis;prognostic;prognostic indicator;Prognostic Marker;prognostic value;Proteins;PTX3 protein;Reagent;Recurrence;Refractory Disease;Reporting;Research Design;Resistance;risk stratification;Role;self-renewal;specific biomarkers;Specimen;stem cell biology;stem cell division;stemness;Survival Rate;Suspensions;targeted treatment;Testing;theranostics;Therapeutic;therapeutic target;Therapeutic Uses;trait;triple-negative invasive breast carcinoma;Trust;tumor;Tumor Burden;tumor initiation;tumorigenic;Xenograft Model;Xenograft procedure

PROJECT_TITLE: Pentraxin-3 in the Pathogenesis and Management of Triple-Negative Breast Cancer


NIH_SPENDING_CATS: Biotechnology;Cancer;Immunotherapy;Orphan Drug;Rare Diseases;Skin Cancer

ORG_CITY: Long Beach

ORG_NAME: SOUTHERN CALIFORNIA INST FOR RES/EDUC

PHR: PROJECT NARRATIVE 1 Merkel cell carcinoma (MCC) is an aggressive skin cancer with increasing incidence and few treatment options. 2 Utilizing clinically relevant animal models and integrated systems-level approaches, we will investigate a novel 3 drug with high translational potential to overcome or circumvent current limitations in therapeutic options.

PI_NAMEs: GAO, LING  (contact)

PROGRAM_OFFICER_NAME: SINGH, ANJU

PROJECT_TERMS: advanced disease;alternative treatment;Animal Model;Antibodies;antitumor effect;Attenuated;Bioinformatics;Biological;Biological Markers;Biological Models;Cancer Model;Case Study;Cell Line;Cell Survival;Cells;chemokine;Clinical;clinically relevant;comorbidity;Death Rate;Dose;drug candidate;Drug Screening;Ecosystem;Epigenetic Process;established cell line;Exhibits;Foundations;Genetic Engineering;Goals;Growth;high-throughput drug screening;Histone Deacetylation;Human;human model;humanized mouse;Image;Immune;immune cell infiltrate;Immune checkpoint inhibitor;immune resistance;Immune system;Immunocompetent;Immunodeficient Mouse;Immunotherapy;improved;In Vitro;in vivo;Incidence;inhibitor;innovation;insight;kinase inhibitor;Laboratories;Malignant Epithelial Cell;Malignant Neoplasms;Mediating;Melanoma;Merkel cell carcinoma;Molecular;Molecular Analysis;mouse model;Mus;neoplastic cell;neuroendocrine cancer;new therapeutic target;novel;novel therapeutics;Pathway interactions;Patient-Focused Outcomes;Patients;pembrolizumab;Pharmaceutical Preparations;Phosphatidylinositide 3-Kinase Inhibitor;Phosphotransferases;Positioning Attribute;potential biomarker;Pre-Clinical Model;programmed cell death protein 1;Protocols documentation;reconstitution;Reporting;Research;Resistance;Resistance development;Resolution;response;single-cell RNA sequencing;Skin Cancer;Solid;Solid Neoplasm;standard of care;success;Survival Rate;System;T-Lymphocyte;targeted treatment;Testing;Therapeutic;therapeutic target;therapy resistant;tool;translational potential;Treatment Efficacy;treatment response;tumor;tumor growth;Tumor Immunity;tumor microenvironment;tumor xenograft;Tumor-Derived;tumor-immune system interactions;United States Food and Drug Administration;Work;Xenograft Model;Xenograft procedure

PROJECT_TITLE: Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment

STUDY_SECTION: DT

STUDY_SECTION_NAME: Developmental Therapeutics Study Section[DT]


NIH_SPENDING_CATS: Bioengineering;Dental, Oral, and Craniofacial Disease;Infectious Diseases

PHR: Advances in engineering approaches offer previously unimagined opportunities to advance the NIDCR 2030 vision of precision oral health for all. To harness this opportunity, a critical mass of cross-trained dentists and engineers engaged in oral and craniofacial research are urgently needed. We will develop this workforce.

PI_NAMEs: KOO, HYUN  (contact);STEBE, KATHLEEN J

PROGRAM_OFFICER_NAME: MCGUIRL, MICHELE

PROJECT_TERMS: Address;Adopted;Applied Research;Artificial Intelligence;Awareness;Binding;Biology;career;career development;Clinical;Clinical Research;Committee Members;Complex;Computational Science;craniofacial;craniofacial complex;Dedications;Dental;Dental caries;Dental Schools;Dentistry;Dentists;Development;Disease;Educational workshop;Elements;Engineering;Enrollment;Environment;experience;Faculty;Family;Funding;Healthcare;Immunity;Industry;innovation;Journals;K-Series Research Career Programs;malignant mouth neoplasm;materials science;Medical;Medicine;Mentors;Mentorship;microbiome;Minority;Mouth Diseases;multidisciplinary;Nanotechnology;novel;novel strategies;Oral;oral biofilm;Oral health;Patients;Pennsylvania;Periodontal Diseases;personalized medicine;Persons;Population;Postdoctoral Fellow;Poverty;Predisposition;programs;Records;Regulatory Affairs;Reproducibility;Research;Research Project Grants;Resources;Robotics;Schools;Science;Scientist;symposium;tissue regeneration;Training;Training Programs;Translational Research;Universities;Vision;Writing

PROJECT_TITLE: Advanced Training at the Interface of Engineering and Oral-Craniofacial Sciences


NIH_SPENDING_CATS: Aging;Brain Disorders;Cancer;Genetics;Neurodegenerative;Neurosciences;Parkinson's Disease;Skin Cancer

ORG_CITY: NEW YORK

ORG_DEPT: NEUROSCIENCES

ORG_NAME: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

PHR: Project Narrative A series of epidemiological studies have shown that people with Parkinson’s disease have a significantly higher risk of developing melanoma and vise-versa, but research on this comorbidity is sparse. The proposed work uses mice carrying a knock-in mutation of the most common genetic contributor to PD and melanoma allograft models to identify the neural mechanisms underlying melanoma risk in PD patients.

PI_NAMEs: DEL VALLE, PAMELA  (contact)

PROGRAM_OFFICER_NAME: ADAMS, GREGORY

PROJECT_TERMS: Allografting;angiogenesis;Animals;Automobile Driving;Axon;behavioral response;Breast Adenocarcinoma;comorbidity;Data;Development;Environment;epidemiology study;Exhibits;experimental study;Genetic;genetic manipulation;Growth;high risk;Implant;In Situ;in vivo;Infiltration;kinase inhibitor;Knock-in;Knock-in Mouse;LRRK2 gene;Macrophage;Malignant Neoplasms;Mediating;Melanoma;Modeling;Mus;Mutation;Neoplasm Metastasis;nerve supply;neural;neurogenesis;neuromechanism;Neurons;Outcome;Parkinson Disease;Patients;Pattern;Persons;pharmacologic;Phosphotransferases;Population;quantitative imaging;Research;response;Risk;screening;Series;Stress;Sympathetic Nervous System;Testing;treatment strategy;tumor;tumor growth;tumor microenvironment;tumor progression;tumor-immune system interactions;Vascularization;Wild Type Mouse;Work

PROJECT_TITLE: Neural Mechanisms Driving Comorbid Parkinson's and Melanoma


PHR: PROJECT NARRATIVE Chronic allograft vasculopathy and fibrosis, also called chronic rejection, is an immunosuppressant-resistant disease that develops in almost half of heart transplants after ten years and remains a leading cause of recipient death one-year post-transplant. The blockage of graft blood vessels and progressive graft scarring causing chronic rejection may reflect failed tissue repair by the recipient's immune system. These studies will pair precise transgenic mice transplant models with cutting-edge technologies to provide previously unattainable insights into how innate and adaptive alloresponses may dysregulate repair processes to cause chronic heart transplant rejection.

PI_NAMEs: TURNQUIST, HETH R (contact)

PROJECT_TERMS: Alloantigen;Allogenic;Allografting;Antigens;arginase;Arteries;B-Lymphocytes;Blood Vessels;Brain Death;Cause of Death;Cell Communication;Cells;Cessation of life;chemokine;Childhood;Chronic;Cicatrix;Clinical;Communication;cytokine;cytotoxicity;Data;Development;directed differentiation;Disease Resistance;Dissection;Event;Fibroblasts;Fibrosis;Generations;Graft Rejection;Growth Factor;Heart Transplantation;Immune;Immune response;Immune system;Immunoglobulins;Immunologics;immunoregulation;Immunosuppressive Agents;improved outcome;Infiltration;Inflammation;Inflammatory;Inflammatory Response;Injury;Innate Immune System;insight;Interferon Type II;Interleukin-13;Interleukins;Ischemia;isoimmunity;Life;Macrophage;Mediating;Memory;Metabolism;Modeling;Molecular;monocyte;Mus;Myeloid Cells;Operative Surgical Procedures;Organ Transplantation;Pathologic;Pathway interactions;Pattern;post-transplant;pre-clinical;prevent;Process;Production;Proliferating;promoter;Publishing;receptor;Regulatory T-Lymphocyte;repaired;Reperfusion Injury;Research;Resolution;response;response to injury;Rodent;Sampling;Secondary to;Signal Transduction;Stress;Stromal Cells;T-Cell Proliferation;T-Lymphocyte;Technology;Testing;tissue repair;Tissues;transcriptomics;Transgenic Mice;transplant model;Transplant Recipients;Transplantation;Trauma;Vascular Diseases

PROJECT_TITLE: Immunoregulatory Mechanisms of IL-33 in Heart Transplantation

STUDY_SECTION: TTT

STUDY_SECTION_NAME: Transplantation, Tolerance, and Tumor Immunology Study Section[TTT]


NIH_SPENDING_CATS: Autoimmune Disease;Clinical Research;Clinical Trials and Supportive Activities;Dental, Oral, and Craniofacial Disease;Digestive Diseases;Eye Disease and Disorders of Vision;Pediatric;Precision Medicine

ORG_CITY: CLEVELAND

ORG_NAME: CASE WESTERN RESERVE UNIVERSITY

ORG_STATE: OH

PHR: Project Narrative: To address the critical need and move the field of treating Childhood Sjögren's disease forward, we propose to use a novel personalized treatment trial strategy called an N-of-1 trial to test potentially effective drugs. The overall goal of the planning phase of this multicenter trial is to complete all the scientific planning and administrative activities required to support a clinical trial.

PI_NAMEs: SINGER, NORA  (contact);STERN, SARA ;TRINQUART, LUDOVIC

PROGRAM_OFFICER_NAME: WANG, YAN Z

PROJECT_TERMS: Acute;Address;Adult;Affect;Arthritis;Autoimmune Diseases;belimumab;Biological;candidate identification;Child;Childhood;Clinical;Clinical Research;Clinical Trials;Collaborations;common symptom;Complication;Consensus;Crossover Design;Data;data management;design;Development;disability;Disease;Disease Outcome;disease phenotype;Disease-Modifying Second-Line Drugs;Double-Blind Method;Dryness;effective intervention;effective therapy;electronic data capture system;Evaluation;Evidence based treatment;experience;eye dryness;Family;Flare;Fostering;Future;Gland;Goals;Grant;Group Meetings;Health Professional;improved;individual patient;Inflammation;Institutional Review Boards;Interview;Knowledge;Lacrimal gland structure;Leadership;Manuals;meetings;member;Mental Health;Methodology;Methods;Minor salivary gland structure;Modeling;Monitor;Multicenter Trials;novel;Outcome;Outcome Measure;Pain;Pamphlets;Parents;Parotid Gland;Parotitis;Patient Outcomes Assessments;patient response;Patients;personalized medicine;Pharmaceutical Preparations;Pharmacotherapy;Phase;Procedures;Protocols documentation;Quality of life;Randomized;randomized trial;Rare Diseases;Recommendation;recruit;Research;Research Personnel;Review Literature;Rheumatology;Safety;Salivary Glands;Series;shared decision making;Sialadenitis;Site;Sjogren's Syndrome;Structure;Surveys;Symptoms;systematic review;Testing;Therapeutic;Therapy Evaluation;Training;treatment strategy;treatment trial;trial design;United States Food and Drug Administration;Xerostomia

PROJECT_TITLE: Planning a childhood sJOgren disease Use of Randomized N-of-1 Evaluation of therapY JOURNEY

STUDY_SECTION_NAME: Special Emphasis Panel[ZAR1 KM (M2)]


ADMINISTERING_IC: EB

IC_NAME: NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING

NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Cancer;Clinical Research;Lung;Lung Cancer;Radiation Oncology

ORG_CITY: DALLAS

ORG_NAME: UT SOUTHWESTERN MEDICAL CENTER

PHR: NARRATIVE Stereotactic body radiation therapy (SBRT) combines precise 3D tumor localization and conformal radiotherapy dose delivery to treat tumors and spare surrounding normal tissues, which yields superior local control and survival benefits for many disease sites. However, the accuracy and safety of SBRT for lung cancer are greatly challenged by the intra-treatment lung tumor and organs-at-risk motion, especially for centrally located tumors that are close to the proximal bronchial tree and other critical organs. This project fulfills the urgent unmet clinical needs of motion management in lung SBRT, by developing the first intra- treatment dynamic cone-beam CT imaging and plan adaptation system to track the intra-treatment patient motion, quantify its dosimetric impact, and adapt the treatment plan to ensure the disease-ablative dose is delivered accurately to tumors and spares surrounding critical organs.

PI_NAMEs: LU, WEIGUO ;ZHANG, YOU  (contact)

PROGRAM_OFFICER_NAME: TORNAI, MARTIN PAUL

PROJECT_TERMS: 3-Dimensional;Address;Anatomy;Artificial Intelligence;Bronchial Tree;cancer care;Cancer Patient;Clinical;Clinical Research;Combined Modality Therapy;Complement;cone-beam computed tomography;Conformal Radiotherapy;Data;design;Development;Diagnosis;digital;Disease;Dose;dose information;dosimetry;Ensure;expectation;Feedback;Film;Future;Goals;Image;Imaging Techniques;improved;indexing;irradiation;Lead;Learning;Lung;Lung Neoplasms;Malignant neoplasm of lung;Measurement;Medical;Methods;Motion;neural;Normal tissue morphology;Organ;Patient-Focused Outcomes;Patients;Phase;preservation;prospective;Radiation;Radiation Dose Unit;Radiation therapy;reconstruction;Reporting;Resolution;Respiration;respiratory;response;Risk;Roentgen Rays;Role;Safety;Signal Transduction;simulation;Site;Source;spatiotemporal;standard of care;success;System;Techniques;Testing;Toxic effect;treatment planning;tumor;Uncertainty;Variant;vector;X-Ray Computed Tomography

PROJECT_TITLE: High-Precision Lung Radiotherapy by Intra-treatment Dynamic Cone-beam CT imaging and Dosimetry-guided Plan Adaptation

STUDY_SECTION: EITA

STUDY_SECTION_NAME: Emerging Imaging Technologies and Applications Study Section[EITA]


ADMINISTERING_IC: FD

IC_NAME: FOOD AND DRUG ADMINISTRATION

ORG_CITY: NASHVILLE

ORG_NAME: TN STATE DEPARTMENT OF AGRICULTURE

PHR: Produce Safety Cooperative Agreement Proposal Narrative Throughout the first five years of engagement in the Produce Safety Cooperative Agreement the Tennessee Department of Agriculture (TDA) adopted the Produce Safety rule by reference, conducted on-farm produce inspections, and provided education/outreach to stakeholders. Moving forward, continued funding support is requested to assist TDA in providing similar services throughout the State. This funding will ensure TDA has the resources and infrastructure necessary to sustain and enhance the State’s produce safety activities with special focus on mitigating outbreaks or other events that could lead to illness.

PI_NAMEs: WITHERS, DANNY WAYNE (contact)

PROGRAM_OFFICER_NAME: VARGO, ADRIANNA

PROJECT_TITLE: Path B Enhance the Capacity and Capabilities of Tennessee's Produce Safety Program in Support of an Integrated Produce Safety System


ORG_CITY: ATLANTA

ORG_NAME: GEORGIA STATE DEPARTMENT OF AGRICULTURE

ORG_STATE: GA

PHR: Application ID 977350  Grant Number TBD  Georgia Department of Agriculture The FDA's Cooperative Agreement Program for States and Territories to Implement a  National Produce Safety Program PAR-21-174  Project Period: 2021-2026 Project Narrative: The Georgia Department of Agriculture, Produce Safety Division is currently positioned to regulate and enforce the FSMA Produce Safety Rule as adopted by reference, and this cooperative agreement will continue to provide Georgia with the necessary resources to maintain and improve the robust Produce Safety Program that has been developed effectively to meet the regulations under the Produce Safety Rule over the last five-year CAP Funding Agreement. The Georgia Department of Agriculture Food Safety Division is seeking to continue its efforts in identifying and addressing food safety issues pertinent to fresh produce grown on Georgia farms and packed in Georgia packing shed operations. Through this cooperative agreement, the GDA plans to continue enhancing and improving the safe production of fresh fruits and vegetables in Georgia, and by promoting compliance among Georgia’s agricultural community with regard to the requirements of FDA’s Regulation “Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption” in key areas such as: a) identify potential risks more quickly; b) establish control measures to minimize the growth of pathogenic organisms; and c) increase the ability to rapidly identify foodborne illness and injury hazards, along with improved educational and outreach opportunities for both producers and consumers, create a positive, food-safety conscious change within the state, from farm to table.

PI_NAMEs: NIELSEN, CRAIG  (contact)

PROJECT_TITLE: Path C Georgia Cooperative Agreement to Implement, improve, and sustain the state Produce Safety Program